This document provides guidance on regulations for the transport of infectious substances and replaces guidance from 2013-2014. It summarizes international regulations from the UN Recommendations on the Transport of Dangerous Goods as well as definitions, classification, packaging and labeling requirements, and other guidance for the safe transport of infectious substances. The document is intended to help shippers, carriers, and recipients understand and comply with transport regulations.
Biosafety & Bloodborne Pathogens Training for Laboratory WorkersElena Fracassa
The Biosafety/Bloodborne Pathogens Course is required for all Wayne State University investigators, staff, and students who work in a lab with materials that are potentially infectious, including human blood, body fluids, tissue, cell lines, animals infected with human pathogens, mammalian viruses, or any agents that are handled at Biosafety Level 2 (BSL2).
Biosafety/Bloodborne Pathogens Training for Laboratory WorkersElena Fracassa
The Biosafety/Bloodborne Pathogens Course is required for all Wayne State University investigators, staff, and students who work in a lab with materials that are potentially infectious, including human blood, body fluids, tissue, cell lines, animals infected with human pathogens, mammalian viruses, or any agents that are handled at Biosafety Level 2 (BSL2).
This document provides an overview of bloodborne pathogen training as required by OSHA. It defines bloodborne pathogens such as hepatitis B, hepatitis C, and HIV. It explains the diseases they can cause and how they are transmitted through contact with blood and bodily fluids. It emphasizes following universal precautions like proper use of personal protective equipment and handwashing. Procedures for exposure incidents and medical follow up are also outlined. The goal is to educate employees on health and safety practices to prevent exposure to bloodborne pathogens.
Wayne State University - Shipping Biological Substances and Dry Ice TrainingElena Fracassa
This document provides training on shipping biological substances and dry ice. It outlines requirements for shipping categories A and B infectious substances, exempt specimens, and dry ice. Shippers must be trained every two years. Category A substances require special handling by EH&S. Category B and exempt materials can be shipped by trained lab staff using triple packaging and following proper labeling, documentation and regulatory requirements. Dry ice also requires specific packaging and ventilation to prevent explosion or oxygen deprivation hazards during transport.
Bio-safety in the lab when dealing with a virus, bacteria and fungiKhadija Saeed
This document provides information on biosafety practices for working with various microorganisms in the lab, including Dengue virus (Risk Group 2), Francisella tularensis (Risk Group 3), and Candida albicans (Risk Group 2). It describes the epidemiology, transmission, survival outside the host, lab hazards, containment requirements, personal protective equipment, disinfection methods, and safe disposal practices for each microorganism. The document also acknowledges the contributions of various authors for compiling the content.
This document discusses biohazards in dentistry and proper waste management. It notes that dental offices generate various types of regulated and non-regulated waste and outlines classifications. Regulated waste like sharps and tissues require special disposal. The document also emphasizes the importance of infection control and preventing cross-contamination both within dental offices and between offices and labs through proper sterilization, disinfection, and labeling of materials.
The document discusses infection control practices in hospitals, including how infections spread, standard and transmission-based precautions, environmental management, and methods for decontamination, sterilization, and disinfection. It provides details on the various disinfectants used in the hospital and guidelines for cleaning different equipment and environmental surfaces. The history and importance of infection control is also reviewed.
The document discusses biohazards and outlines procedures for ensuring environmental safety when working with biological materials. It defines biohazards as biological substances that threaten human health, such as viruses, bacteria, and toxins. Different levels of biocontainment are used depending on the risk level of the pathogens being handled, with Level 1 requiring minimal precautions and Level 4 the highest level of isolation for dangerous pathogens lacking vaccines or treatments. Proper use of warning signs, protective equipment, sterilization processes, and segregated work areas are emphasized for reducing risks of exposure or contamination.
Biosafety & Bloodborne Pathogens Training for Laboratory WorkersElena Fracassa
The Biosafety/Bloodborne Pathogens Course is required for all Wayne State University investigators, staff, and students who work in a lab with materials that are potentially infectious, including human blood, body fluids, tissue, cell lines, animals infected with human pathogens, mammalian viruses, or any agents that are handled at Biosafety Level 2 (BSL2).
Biosafety/Bloodborne Pathogens Training for Laboratory WorkersElena Fracassa
The Biosafety/Bloodborne Pathogens Course is required for all Wayne State University investigators, staff, and students who work in a lab with materials that are potentially infectious, including human blood, body fluids, tissue, cell lines, animals infected with human pathogens, mammalian viruses, or any agents that are handled at Biosafety Level 2 (BSL2).
This document provides an overview of bloodborne pathogen training as required by OSHA. It defines bloodborne pathogens such as hepatitis B, hepatitis C, and HIV. It explains the diseases they can cause and how they are transmitted through contact with blood and bodily fluids. It emphasizes following universal precautions like proper use of personal protective equipment and handwashing. Procedures for exposure incidents and medical follow up are also outlined. The goal is to educate employees on health and safety practices to prevent exposure to bloodborne pathogens.
Wayne State University - Shipping Biological Substances and Dry Ice TrainingElena Fracassa
This document provides training on shipping biological substances and dry ice. It outlines requirements for shipping categories A and B infectious substances, exempt specimens, and dry ice. Shippers must be trained every two years. Category A substances require special handling by EH&S. Category B and exempt materials can be shipped by trained lab staff using triple packaging and following proper labeling, documentation and regulatory requirements. Dry ice also requires specific packaging and ventilation to prevent explosion or oxygen deprivation hazards during transport.
Bio-safety in the lab when dealing with a virus, bacteria and fungiKhadija Saeed
This document provides information on biosafety practices for working with various microorganisms in the lab, including Dengue virus (Risk Group 2), Francisella tularensis (Risk Group 3), and Candida albicans (Risk Group 2). It describes the epidemiology, transmission, survival outside the host, lab hazards, containment requirements, personal protective equipment, disinfection methods, and safe disposal practices for each microorganism. The document also acknowledges the contributions of various authors for compiling the content.
This document discusses biohazards in dentistry and proper waste management. It notes that dental offices generate various types of regulated and non-regulated waste and outlines classifications. Regulated waste like sharps and tissues require special disposal. The document also emphasizes the importance of infection control and preventing cross-contamination both within dental offices and between offices and labs through proper sterilization, disinfection, and labeling of materials.
The document discusses infection control practices in hospitals, including how infections spread, standard and transmission-based precautions, environmental management, and methods for decontamination, sterilization, and disinfection. It provides details on the various disinfectants used in the hospital and guidelines for cleaning different equipment and environmental surfaces. The history and importance of infection control is also reviewed.
The document discusses biohazards and outlines procedures for ensuring environmental safety when working with biological materials. It defines biohazards as biological substances that threaten human health, such as viruses, bacteria, and toxins. Different levels of biocontainment are used depending on the risk level of the pathogens being handled, with Level 1 requiring minimal precautions and Level 4 the highest level of isolation for dangerous pathogens lacking vaccines or treatments. Proper use of warning signs, protective equipment, sterilization processes, and segregated work areas are emphasized for reducing risks of exposure or contamination.
An infection occurs when pathogens invade the body and reproduce, potentially causing disease. Microorganisms are transmitted through body fluids, direct contact, droplets, and contaminated surfaces. Portals of entry include mucous membranes and breaks in the skin. Hospitals present increased infection risks due to patients' health issues, invasive procedures, and virulent pathogen strains. Standard precautions like hand washing, personal protective equipment, sharp handling protocols, and waste management can reduce transmission when applied consistently. Staff education also helps prevent the spread of infections.
The document outlines the key components of an effective hospital infection control program, including establishing an infection control team, committee, and manual. It emphasizes the importance of surveillance to monitor infection rates, preventive activities like standard precautions, and staff training. Standard precautions include proper hand hygiene, use of barriers like gloves and gowns, safe handling of sharps and contaminated materials, and maintaining a clean patient environment. The goal of the program is to reduce infection risk and increase safety.
This document provides information about preparing workplaces for an influenza pandemic. It discusses the potential impact of a pandemic on workers and businesses. It outlines the steps employers should take to reduce exposure risks, including conducting risk assessments, implementing infection control measures, communicating with employees, and training workers. Resources from OSHA and other organizations are recommended to help employers develop pandemic preparedness plans.
This document discusses infection control and prevention of disease transmission in healthcare facilities. It emphasizes the importance of standard procedures to prevent infections from spreading. It outlines the roles and responsibilities of an infection control committee and discusses various pathogens, modes of transmission, and strategies for proper waste disposal and management of exposures to infectious agents.
Lecture 5 : control of substances hazard to healthraghdasaad6
COSHH is UK law requiring employers to control substances hazardous to health. It involves identifying health hazards, conducting risk assessments, implementing control measures like PPE, providing training, monitoring health, and planning for emergencies. Hazardous substances include chemicals, fumes, dusts and vapors. Employers must prevent exposure, maintain control measures, provide instruction and training, and conduct health surveillance. Employees must follow safety procedures, wear PPE, report issues, and attend medical check-ups. When working with blood and tissues, universal precautions like gloves, safety glasses and sharps containers help prevent transmission of pathogens like hepatitis B and HIV.
This document provides an overview of laboratory safety policies and procedures. It discusses requirements for laboratory safety including ensuring proper equipment maintenance and documentation of hazards. It also covers personal protective equipment, safety practices regarding chemicals, biological hazards, and waste disposal. Biological safety equipment like biosafety cabinets are explained. Procedures for handling spills, injuries, and incidents are provided to ensure safe operation of the laboratory.
The document discusses biological hazards, including:
1. Types of biological hazards such as bacteria, viruses, and fungi and how they can enter the body through inhalation, absorption, ingestion, or injection.
2. How biological hazards are spread from person to person and examples of diseases caused by different types of bacteria and viruses.
3. There are four levels of biological hazards ranging from relatively harmless microorganisms to those that can cause death, and appropriate personal protective equipment and disposal methods vary depending on the level.
This document provides an overview and introduction to a course on medical virology. It outlines the learning objectives which include gaining knowledge of biosafety guidelines, laboratory safety procedures, specimen collection and processing, cell culture techniques, and molecular detection methods for viruses. The document also acknowledges sources of images used and provides copyright information.
The document discusses various aspects of infection control including:
1) Key contributors to germ theory such as Lister, Pasteur, and Semmelweis.
2) Different types of microorganisms like bacteria, fungi, viruses, and their roles in infection.
3) Conditions required for bacterial growth and transmission of infections.
4) Stages of the infection process and the body's defense systems against infection.
5) Methods of infection control including standard precautions, medical asepsis, surgical asepsis, handwashing, and different forms of disinfection and sterilization.
This document discusses laboratory biosafety in the molecular diagnosis of emerging respiratory infectious diseases. It covers the changing landscape of infectious diseases, PCR-based detection of pathogens like MERS-CoV, biosafety principles, risk assessment, containment levels, and safe handling practices. Specific considerations are given to conducting molecular detection of MERS-CoV, which is a biosafety level 3 pathogen, in a way that protects laboratory workers, the community, and the environment.
This document summarizes research presented by Dr. Mohamed El Zowalaty on avian influenza virus surveillance. It describes efforts to isolate avian influenza viruses from polymerase chain reaction-negative waterfowl samples, experiments testing different sample types and virus isolation methods, and identification of various avian influenza virus subtypes isolated including H5 strains. The research aimed to improve avian influenza virus detection and surveillance methods.
This document discusses key concepts of infection control, including definitions of infection and colonization. It notes that healthcare-associated infections are a major problem, with higher rates in developing countries. Factors influencing infection risk include microbial agents, patient susceptibility, and environmental factors. The document outlines standard and transmission-based precautions to prevent infection spread. It emphasizes hand hygiene, personal protective equipment, and cleaning and disinfection as core infection control measures.
deals with biosafety in medical labs. universal safety precautions included. Includes updated 8 categories and colour coding for BMW management. Being a budding microbiologist, kept it focused on microbiology lab
This document discusses infection control in dental clinics. It begins with terminology related to infection control, including definitions of infection, sterilization, disinfection, asepsis, antiseptics, and more. It then covers the history of infection control practices dating back to Joseph Lister's pioneering work in the late 19th century. The objectives, modes of transmission in dental clinics, and guidelines for infection control are outlined. Methods of sterilization like heat, chemicals, and newer technologies are described. Factors that impact the efficacy of sterilization processes are also summarized.
This document discusses new methods for cleaning ICU rooms. It notes current problems like inadequate handwashing facilities, overcrowding, and lack of isolation and separation of clean and dirty areas. It explores strategies like enhanced cleaning with dedicated teams, antimicrobial surfaces, touchless cleaning robots, and no-touch decontamination methods like hydrogen peroxide vapor. Various disinfectants are compared, and monitoring techniques like ATP bioluminescence are presented. The document concludes that UV light devices, hydrogen peroxide vapor, and ultra-microfiber cloths represent promising new cleaning methods, but more comparative studies are still needed.
The document discusses components of biosecurity including food safety, zoonoses, animal and plant health, invasive species, and living modified organisms. It provides definitions and objectives of biosecurity, describes its importance in agriculture and historical disease examples. Factors influencing biosecurity like globalization and international groups supporting biosecurity efforts are examined.
The document summarizes the 55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. The report outlines the Committee's discussions and adoption of several new guidelines and standards related to good manufacturing practices, quality control of medicines, international reference materials, and regulatory guidance. Key items adopted include revised GMP guidelines for sterile products and water for pharmaceutical use, as well as new guidelines on data integrity, bioequivalence waivers for essential medicines, and certification schemes for medicine quality.
The document summarizes the 55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. The report adopted several new guidelines and guidance texts related to good manufacturing practices, data integrity, regulatory practices, specifications for medicines including those for COVID-19, and other quality assurance areas. It also recommended texts for inclusion in The International Pharmacopoeia and outlined the Committee's views and recommendations.
WHO Expert Committee on specifications for pharmaceutical preparationsPostgradoMLCC
This document provides an overview of the 44th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. It discusses WHO's work related to ensuring quality, safety and efficacy of medicines through setting international standards for medicines and providing guidance on good practices for manufacturing, quality control testing, and distribution of pharmaceuticals. The report also provides updates on WHO prequalification of priority medicines and related quality assurance programs and initiatives.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations works to develop clear, independent, and practical standards for quality assurance of medicines through worldwide consultation and consensus building. The Committee adopted new guidelines at its meeting, including revised procedures for developing monographs in The International Pharmacopoeia and guidance for storage and transport of temperature-sensitive pharmaceutical products.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations works to develop clear, independent, and practical standards for quality assurance of medicines through worldwide consultation and consensus building. The Committee adopted new guidelines at its meeting, including revised procedures for developing monographs in The International Pharmacopoeia and guidance for storage and transport of temperature-sensitive pharmaceutical products.
An infection occurs when pathogens invade the body and reproduce, potentially causing disease. Microorganisms are transmitted through body fluids, direct contact, droplets, and contaminated surfaces. Portals of entry include mucous membranes and breaks in the skin. Hospitals present increased infection risks due to patients' health issues, invasive procedures, and virulent pathogen strains. Standard precautions like hand washing, personal protective equipment, sharp handling protocols, and waste management can reduce transmission when applied consistently. Staff education also helps prevent the spread of infections.
The document outlines the key components of an effective hospital infection control program, including establishing an infection control team, committee, and manual. It emphasizes the importance of surveillance to monitor infection rates, preventive activities like standard precautions, and staff training. Standard precautions include proper hand hygiene, use of barriers like gloves and gowns, safe handling of sharps and contaminated materials, and maintaining a clean patient environment. The goal of the program is to reduce infection risk and increase safety.
This document provides information about preparing workplaces for an influenza pandemic. It discusses the potential impact of a pandemic on workers and businesses. It outlines the steps employers should take to reduce exposure risks, including conducting risk assessments, implementing infection control measures, communicating with employees, and training workers. Resources from OSHA and other organizations are recommended to help employers develop pandemic preparedness plans.
This document discusses infection control and prevention of disease transmission in healthcare facilities. It emphasizes the importance of standard procedures to prevent infections from spreading. It outlines the roles and responsibilities of an infection control committee and discusses various pathogens, modes of transmission, and strategies for proper waste disposal and management of exposures to infectious agents.
Lecture 5 : control of substances hazard to healthraghdasaad6
COSHH is UK law requiring employers to control substances hazardous to health. It involves identifying health hazards, conducting risk assessments, implementing control measures like PPE, providing training, monitoring health, and planning for emergencies. Hazardous substances include chemicals, fumes, dusts and vapors. Employers must prevent exposure, maintain control measures, provide instruction and training, and conduct health surveillance. Employees must follow safety procedures, wear PPE, report issues, and attend medical check-ups. When working with blood and tissues, universal precautions like gloves, safety glasses and sharps containers help prevent transmission of pathogens like hepatitis B and HIV.
This document provides an overview of laboratory safety policies and procedures. It discusses requirements for laboratory safety including ensuring proper equipment maintenance and documentation of hazards. It also covers personal protective equipment, safety practices regarding chemicals, biological hazards, and waste disposal. Biological safety equipment like biosafety cabinets are explained. Procedures for handling spills, injuries, and incidents are provided to ensure safe operation of the laboratory.
The document discusses biological hazards, including:
1. Types of biological hazards such as bacteria, viruses, and fungi and how they can enter the body through inhalation, absorption, ingestion, or injection.
2. How biological hazards are spread from person to person and examples of diseases caused by different types of bacteria and viruses.
3. There are four levels of biological hazards ranging from relatively harmless microorganisms to those that can cause death, and appropriate personal protective equipment and disposal methods vary depending on the level.
This document provides an overview and introduction to a course on medical virology. It outlines the learning objectives which include gaining knowledge of biosafety guidelines, laboratory safety procedures, specimen collection and processing, cell culture techniques, and molecular detection methods for viruses. The document also acknowledges sources of images used and provides copyright information.
The document discusses various aspects of infection control including:
1) Key contributors to germ theory such as Lister, Pasteur, and Semmelweis.
2) Different types of microorganisms like bacteria, fungi, viruses, and their roles in infection.
3) Conditions required for bacterial growth and transmission of infections.
4) Stages of the infection process and the body's defense systems against infection.
5) Methods of infection control including standard precautions, medical asepsis, surgical asepsis, handwashing, and different forms of disinfection and sterilization.
This document discusses laboratory biosafety in the molecular diagnosis of emerging respiratory infectious diseases. It covers the changing landscape of infectious diseases, PCR-based detection of pathogens like MERS-CoV, biosafety principles, risk assessment, containment levels, and safe handling practices. Specific considerations are given to conducting molecular detection of MERS-CoV, which is a biosafety level 3 pathogen, in a way that protects laboratory workers, the community, and the environment.
This document summarizes research presented by Dr. Mohamed El Zowalaty on avian influenza virus surveillance. It describes efforts to isolate avian influenza viruses from polymerase chain reaction-negative waterfowl samples, experiments testing different sample types and virus isolation methods, and identification of various avian influenza virus subtypes isolated including H5 strains. The research aimed to improve avian influenza virus detection and surveillance methods.
This document discusses key concepts of infection control, including definitions of infection and colonization. It notes that healthcare-associated infections are a major problem, with higher rates in developing countries. Factors influencing infection risk include microbial agents, patient susceptibility, and environmental factors. The document outlines standard and transmission-based precautions to prevent infection spread. It emphasizes hand hygiene, personal protective equipment, and cleaning and disinfection as core infection control measures.
deals with biosafety in medical labs. universal safety precautions included. Includes updated 8 categories and colour coding for BMW management. Being a budding microbiologist, kept it focused on microbiology lab
This document discusses infection control in dental clinics. It begins with terminology related to infection control, including definitions of infection, sterilization, disinfection, asepsis, antiseptics, and more. It then covers the history of infection control practices dating back to Joseph Lister's pioneering work in the late 19th century. The objectives, modes of transmission in dental clinics, and guidelines for infection control are outlined. Methods of sterilization like heat, chemicals, and newer technologies are described. Factors that impact the efficacy of sterilization processes are also summarized.
This document discusses new methods for cleaning ICU rooms. It notes current problems like inadequate handwashing facilities, overcrowding, and lack of isolation and separation of clean and dirty areas. It explores strategies like enhanced cleaning with dedicated teams, antimicrobial surfaces, touchless cleaning robots, and no-touch decontamination methods like hydrogen peroxide vapor. Various disinfectants are compared, and monitoring techniques like ATP bioluminescence are presented. The document concludes that UV light devices, hydrogen peroxide vapor, and ultra-microfiber cloths represent promising new cleaning methods, but more comparative studies are still needed.
The document discusses components of biosecurity including food safety, zoonoses, animal and plant health, invasive species, and living modified organisms. It provides definitions and objectives of biosecurity, describes its importance in agriculture and historical disease examples. Factors influencing biosecurity like globalization and international groups supporting biosecurity efforts are examined.
The document summarizes the 55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. The report outlines the Committee's discussions and adoption of several new guidelines and standards related to good manufacturing practices, quality control of medicines, international reference materials, and regulatory guidance. Key items adopted include revised GMP guidelines for sterile products and water for pharmaceutical use, as well as new guidelines on data integrity, bioequivalence waivers for essential medicines, and certification schemes for medicine quality.
The document summarizes the 55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. The report adopted several new guidelines and guidance texts related to good manufacturing practices, data integrity, regulatory practices, specifications for medicines including those for COVID-19, and other quality assurance areas. It also recommended texts for inclusion in The International Pharmacopoeia and outlined the Committee's views and recommendations.
WHO Expert Committee on specifications for pharmaceutical preparationsPostgradoMLCC
This document provides an overview of the 44th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. It discusses WHO's work related to ensuring quality, safety and efficacy of medicines through setting international standards for medicines and providing guidance on good practices for manufacturing, quality control testing, and distribution of pharmaceuticals. The report also provides updates on WHO prequalification of priority medicines and related quality assurance programs and initiatives.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations works to develop clear, independent, and practical standards for quality assurance of medicines through worldwide consultation and consensus building. The Committee adopted new guidelines at its meeting, including revised procedures for developing monographs in The International Pharmacopoeia and guidance for storage and transport of temperature-sensitive pharmaceutical products.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations works to develop clear, independent, and practical standards for quality assurance of medicines through worldwide consultation and consensus building. The Committee adopted new guidelines at its meeting, including revised procedures for developing monographs in The International Pharmacopoeia and guidance for storage and transport of temperature-sensitive pharmaceutical products.
The document provides guidelines from the World Health Organization (WHO) for malaria prevention and control. It recommends several vector control interventions for large-scale deployment, including pyrethroid-only long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) using a WHO-prequalified insecticide. It conditionally recommends pyrethroid-PBO nets and larviciding as supplementary measures in some settings. It recommends ensuring access to effective vector control through ITNs or IRS at optimal coverage levels for populations at risk of malaria.
This document provides an introduction to Volume 2 of the WHO publication "Quality assurance of pharmaceuticals: a compendium of guidelines and related materials". Volume 2 focuses on good manufacturing practices (GMP) and inspection of pharmaceutical manufacturers and distribution channels. It summarizes the guidelines contained in the volume and provides context on WHO's role in establishing international quality standards for pharmaceuticals.
This document discusses chemicals in the workplace and their impact on worker health and the environment. It notes that while chemicals are essential to modern life and industry, exposures can negatively impact health. Chemical exposures are widespread and affect many sectors of the economy. Occupational diseases from chemical exposures represent a major global burden and cost billions in lost productivity. Effective management of chemicals in the workplace and protection of workers is an ongoing challenge requiring efforts at national and international levels.
This document provides guidelines for quality control testing of herbal materials. It describes general considerations for methods, including use of the metric system, precision of measurements, calculation of results, and establishment of limits. Reagents and solutions are given specific designations. Temperature is generally room temperature unless otherwise specified. The document aims to support development of national standards for herbal materials.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations met in October 2004 to consider matters concerning quality assurance of pharmaceuticals. Key topics discussed included proposed monographs for inclusion in The International Pharmacopoeia, quality specifications for antiretroviral and antituberculosis drugs, good manufacturing practices, inspection procedures, distribution standards, and guidelines for fixed-dose combination medicines. The Committee adopted several new standards and guidelines and made recommendations on advancing additional work in priority areas.
This document provides benchmarks for training in osteopathy. It discusses the basic principles of osteopathy, including its philosophy and structure-function relationship models. It outlines categories of training programs and core competencies. A benchmark training curriculum for osteopathy is presented, covering basic sciences, clinical sciences, and clinical training. Guidelines are provided for adapting Type I research-based programs to Type II programs where research is still maturing. The document also discusses safety issues related to osteopathic techniques.
A framework for malaria elimination.pdfEdsonFidelis5
This document provides a framework for malaria elimination. It outlines principles and strategies for eliminating malaria, including enhancing vector control and case detection. It discusses management and planning processes, such as creating an independent advisory committee. It also addresses preventing malaria re-establishment after elimination and certifying elimination. The framework aims to guide countries in developing effective elimination programs aligned with WHO strategies.
Marketing of breast milk substitutes: national implementation of the international code, status report 2020.
Este relatório fornece informações atualizadas sobre o status da implementação do Código Internacional de Comercialização de Substitutos do Leite Materno (NBCAL no Brasil) e subsequentes resoluções relevantes da Assembléia Mundial da Saúde (“o Código”) nos países. Apresenta o status legal do Código, incluindo até que ponto suas disposições foram incorporadas nas medidas legais nacionais.
Dado o importante papel dos profissionais de saúde na proteção de mulheres grávidas, mães e seus bebês da promoção inadequada de fórmulas infantis, o relatório de 2020 destaca disposições específicas consideradas particularmente úteis para abordar e eliminar a promoção de substitutos do leite materno, mamadeiras e bicos aos profissionais de saúde e nas unidades de saúde, e fornece uma extensa análise das medidas legais adotadas para proibir a promoção para os profissionais de saúde e nas unidades de saúde.
Neste relatório, um novo algoritmo de pontuação foi usado para classificar a legislação dos países. Os métodos de pontuação permitem a classificação padronizada de países, seguindo os critérios acordados entre a OMS, UNICEF e IBFAN. As medidas legais para todos os países foram analisadas com base em uma lista de verificação padronizada e expandida com um algoritmo para facilitar uma classificação sistemática e objetiva dos países de acordo com o seu alinhamento com o Código. Desde 2018, continua havendo progresso na promoção e proteção do aleitamento materno, globalmente e nos países. Medidas mais robustas para coibir práticas de marketing prejudiciais contínuas por fabricantes e distribuidores de fórmulas infantis foram adotadas em vários países.
Thahira Shireen Mustafa
Departamento de Nutrição e Segurança Alimentar
Organização Mundial da Saúde
Muito bom!
Prof. Marcus Renato de Carvalho
www.agostodourado.com
The document summarizes the report from the Second WHO Expert Meeting on Critically Important Antimicrobials for Human Medicine held in Copenhagen from 29-31 May 2007. The meeting reviewed and updated a previous list of critically important antimicrobial classes developed at a 2005 meeting in Canberra, considering factors like new developments in antimicrobial resistance and expert committee recommendations. Participants modified the document title to clarify the purpose is for developing risk management strategies for antimicrobial resistance from non-human use. Relatively few changes were needed to update the categorization of antimicrobials. The group also prioritized agents within the critically important category to focus risk management strategies on quinolones, 3rd/4th generation cephalosporins,
This document presents evidence on maternal nutrition and its impact on obesity and noncommunicable diseases. It provides an overview of national recommendations for nutrition, physical activity, and weight gain during pregnancy in WHO European countries. The key findings are:
- Many countries have recommendations for maternal nutrition, physical activity, and weight gain, but capacity and implementation vary.
- National guidelines focus on nutrient and calorie needs during pregnancy but could be strengthened for at-risk groups.
- Most countries have recommendations for newborn and child nutrition, but supportive policies like paid parental leave vary significantly.
- Opportunities for improving guidelines, healthcare professional training, surveillance, and support for maternal and child health were identified.
WHO Pharmaceuticals NEWSLETTER , 2019 No.2.
The WHO Pharmaceuticals Newsletter provides you
with the latest information on the safety of medicines
and legal actions taken by regulatory authorities around
the world. It also provides signals based on information
derived from the WHO global database of individual
case safety reports
"Pharmaceutical sciences
and the challenge for a healthcare focused agenda for pharmacists training"
(A interface ensino-profissão no desenvolvimento das Ciências Farmacêuticas)
Rogério Gaspar
(Presidente da SPCF)
21.SET.2016
Bio Medical Waste Management And Handling Rules 1998ASHISH SINGH
The document discusses India's Bio-Medical Waste (Management and Handling) Rules 1998 which were established to regulate the management of biomedical waste from healthcare facilities. It defines biomedical waste and categories it based on potential hazards. The rules require all waste generators to treat and dispose of waste properly to prevent risks to public health and the environment. Facilities must segregate waste, maintain records, and report any accidents. The rules aim to formalize waste handling practices in India and prevent improper disposal of biomedical waste.
WHO Good Practices for Pharmaceutical Microbiology LaboratoriesPostgradoMLCC
This document provides guidelines for good practices in pharmaceutical microbiology laboratories. It outlines requirements for personnel, facilities, equipment, reagents, reference materials, sampling, testing procedures, quality assurance and reporting. The document establishes procedures for method validation, equipment qualification, environmental monitoring, cleaning and waste disposal. It provides guidance on conducting sterility testing and maintaining reference cultures in compliance with international standards. Comments on the draft are requested by October 2010.
Similar to Guía Sobre la Reglamentación Relativa al Transporte de Sustancias Infecciosas 2015–2016. OMS 2015 (20)
This chapter discusses the evolution and diversification of climbers in angiosperms. Climbers have evolved independently multiple times within angiosperms, as they are found among ancestral groups of both dicots and monocots. Their phylogenetic diversity supports multiple origins of the climbing habit. Climbers provide ecological benefits by utilizing sunlight, water, and nutrients efficiently with minimal structural support. They also serve as an important food source and provide medicinal products. Fossil evidence suggests climbers played a key role in past tropical forest ecosystems, though their contribution to Mesozoic forests was likely smaller due to fewer detailed studies identifying fossil lianas. Overall, climbers demonstrate a key innovation in angiosperm evolution through their species richness
Este documento presenta el Vademécum Farmacoterapéutico del Ecuador 2009, una publicación del Ministerio de Salud Pública y otros organismos que provee información sobre el uso adecuado de medicamentos. Incluye autoridades, equipo de trabajo, contenido e información importante sobre posología, efectos adversos, uso de medicamentos durante el embarazo y lactancia, y tratamiento de intoxicaciones.
Este documento presenta el reporte de una práctica de laboratorio sobre la intoxicación por formaldehído en un cobayo. El objetivo fue observar la sintomatología del animal intoxicado y determinar la presencia de formaldehído mediante reacciones químicas. Se administró formaldehído al 40% al cobayo por vía intraperitoneal, se observó la sintomatología y luego de la muerte se destilaron las vísceras para realizar reacciones que confirmaron la presencia de formaldehído.
Este documento presenta cuadros con las dosis agudas, crónicas y letales de varios tóxicos volátiles, minerales, ácidos y álcalis cáusticos. Proporciona los niveles de exposición considerados seguros y peligrosos por vía de inhalación, ingestión y contacto dérmico para cada sustancia, así como sus efectos sobre la salud humana. El documento incluye enlaces a páginas web con información adicional sobre la toxicidad de cada compuesto químico.
Este documento presenta una tabla de sustancias clasificadas como cancerígenas y/o mutágenas de acuerdo con la normativa de la Unión Europea. La tabla incluye sustancias como el amianto, el benceno, el cloruro de vinilo y diversos compuestos de cromo y níquel. También se indica que a estas sustancias les es aplicable la legislación española sobre protección de trabajadores expuestos a agentes cancerígenos.
La vitamina B12 contribuye a mantener en buen estado el sistema nervioso y los glóbulos rojos. La deficiencia de vitamina B12 puede causar anemia megaloblástica y neuropatías. El diagnóstico se realiza mediante exámenes clínicos y de laboratorio que muestran niveles bajos de vitamina B12, alta homocisteína y ácido metilmalónico. El tratamiento consiste en la suplementación de vitamina B12 de forma oral o inyectable.
Este documento presenta la codificación de la Ley para la formulación, fabricación, importación, comercialización y uso de plaguicidas y productos afines de uso agrícola en Ecuador. Establece las facultades del Ministerio de Agricultura y Ganadería en relación con el registro y control de plaguicidas. También regula aspectos como la clasificación, etiquetado, almacenamiento, transporte, aplicación y residuos máximos permitidos de plaguicidas. Finalmente, titula las responsabilidades de formuladores, empresas, transportistas y empleadores en el mane
Este documento proporciona información sobre varios plaguicidas agrícolas autorizados para su uso en Ecuador. Incluye el nombre genérico y comercial de cada plaguicida, su uso, concentración, categoría de toxicidad, tipo de formulación, empresa fabricante y dosis recomendada. Los plaguicidas mencionados son para el control de insectos, hongos y malezas en cultivos como maíz, arroz, banano, papa y otros. La mayoría son fabricados por empresas multinacionales pero también hay algunos producidos localmente en Ecuador.
El documento habla sobre varios tipos de toxinas y sustancias potencialmente dañinas que pueden encontrarse en los alimentos, incluyendo aditivos, fármacos aplicados a animales, toxinas pirológicas, plaguicidas, micotoxinas producidas por hongos, sustancias antinutritivas, metales pesados, intoxicaciones de mariscos e intolerancias alimentarias.
Este documento presenta una guía sobre el desarrollo preclínico de medicamentos. Comienza explicando las diferentes fases del desarrollo de medicamentos, incluyendo la fase de descubrimiento, preclínica, clínica y aprobación. Luego, se enfoca en la fase preclínica, describiendo su entorno regulatorio, clasificaciones de medicamentos, y los estudios de eficacia y seguridad requeridos. Finalmente, incluye casos prácticos y proveedores de servicios preclínicos.
Este documento proporciona información sobre bioterios y el cuidado de animales de laboratorio. Explica que un bioterio es un departamento especializado en la reproducción y mantenimiento de animales de laboratorio bajo condiciones óptimas para su uso en investigación científica. Describe los principios éticos de reducir, reemplazar y refinar el uso de animales, y las especies comunes como ratones, ratas y cobayos. Resalta la importancia de mantener ambientes estandarizados, genética controlada y bienestar animal en los bioterios
El cáncer se está convirtiendo en una de las principales causas de muerte en el mundo debido al aumento de la exposición a carcinógenos como el humo de tabaco y contaminantes ambientales y ocupacionales. Se espera que el número de casos de cáncer se duplique para el año 2010 a causa de la disminución de otras causas de muerte y el aumento de la edad promedio de la población. La mayoría de los carcinógenos químicos son mutagénicos y actúan induciendo alteraciones genéticas celulares de forma
El documento proporciona una introducción a las técnicas cromatográficas. Explica que la cromatografía involucra poner en contacto dos fases mutuamente inmiscibles, la fase estacionaria y la fase móvil. Define varios términos clave como fase estacionaria, fase móvil, elución y componentes de la muestra. También describe los principales mecanismos de separación cromatográfica como la adsorción, el reparto, la exclusión y el intercambio iónico. Finalmente
Este documento presenta una lista de 20 plaguicidas comúnmente utilizados en la agricultura ecuatoriana. Para cada plaguicida, se proporciona su nombre, uso, categoría de toxicidad según la norma técnica ecuatoriana INEN 1 898. La mayoría de los plaguicidas se clasifican como moderadamente peligrosos o ligeramente peligrosos, aunque algunos se consideran altamente peligrosos. El documento también incluye referencias bibliográficas y extractos de la ley ecuatoriana sobre el uso y com
Este documento discute la temperatura corporal durante el embarazo y los riesgos de la hipertermia. Explica que la temperatura basal normalmente aumenta solo 0.3°C durante el embarazo debido al aumento del metabolismo y los cambios hormonales, pero que una temperatura de 38.3°C o más, especialmente si dura mucho tiempo, puede ser preocupante. También resume los estudios que muestran un mayor riesgo de defectos del tubo neural si una mujer embarazada tiene fiebre al principio del embarazo, aunque se necesitan más
Este documento presenta una introducción general a la inmunología. Explica que el sistema inmunológico está compuesto por mecanismos de defensa innatos y adquiridos que protegen al organismo de agentes nocivos. Describe las principales células y moléculas involucradas, incluyendo linfocitos, macrófagos y citoquinas. También distingue entre la inmunidad innata general y la inmunidad adquirida específica mediada por linfocitos.
Este documento presenta directrices para la eliminación segura de productos farmacéuticos no deseados durante y después de una emergencia. Proporciona información sobre los costos asociados con la eliminación, los pasos a seguir como la clasificación y eliminación de los productos, y los riesgos de una eliminación inadecuada. Además, describe métodos para la eliminación como la devolución al donante, incineración u otros tratamientos para asegurar la protección de la salud y el medio ambiente. El objetivo es brindar orientación a
Este manual proporciona información sobre el mantenimiento de equipos de laboratorio. Cubre 18 tipos de equipos comúnmente utilizados en laboratorios, incluyendo analizadores, balanzas, baños de María, cabinas de seguridad biológica y centrífugas. Para cada equipo, describe sus principios de operación, requisitos de servicio y rutinas de mantenimiento recomendadas. El objetivo del manual es apoyar al personal de laboratorio en el uso y mantenimiento adecuado de este equipamiento.
Este documento presenta un manual de bioseguridad para laboratorios de tuberculosis. Proporciona recomendaciones sobre la clasificación de riesgos de laboratorios, medidas de bioseguridad esenciales, características y medidas para laboratorios de bajo, moderado y alto riesgo, equipo de seguridad, equipo de protección personal, y planes de emergencia. El objetivo es establecer criterios mínimos de bioseguridad para pruebas de tuberculosis en diferentes contextos, tomando en cuenta factores como la carga bacteriana y la viabilidad de
Este documento presenta la tercera edición del Manual de Bioseguridad en el Laboratorio publicado por la Organización Mundial de la Salud. El manual ha sido revisado y ampliado para abordar los nuevos desafíos en bioseguridad, como la evaluación de riesgos, el uso de la tecnología del ADN recombinante y las directrices para la certificación de laboratorios. El manual sigue siendo una guía fundamental para establecer programas de seguridad biológica en los laboratorios de todo el mundo.
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
3. ii
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Acknowledgement
The extracts from the Recommendations on the Transport of Dangerous Goods, Model Regulations,
18th revised edition, New York and Geneva, United Nations, 2013 are reproduced by kind permission
of the United Nations.
Note to the reader:
This document replaces the WHO Guidance on regulations for the
transport of infectious substances 2013-2014.
For the reader's ease, updated text is highlighted as follows:
modified text
5. 1
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Contents
Contents
Acknowledgement ...................................................................................................................................... 3
Contents....................................................................................................................................................... 1
International regulations ........................................................................................................................ 4
National regulations............................................................................................................................... 4
Definitions ................................................................................................................................................. 5
Infectious substances.............................................................................................................................. 5
Cultures.................................................................................................................................................. 5
Patient specimens................................................................................................................................... 5
Biological products ................................................................................................................................ 5
Medical or clinical wastes...................................................................................................................... 5
Classification............................................................................................................................................... 6
Category A............................................................................................................................................. 6
Category B ............................................................................................................................................. 6
Exemptions ............................................................................................................................................ 6
Biological products ................................................................................................................................ 8
Genetically modified microorganisms and organisms ........................................................................... 8
Medical or clinical wastes...................................................................................................................... 8
Infected animals..................................................................................................................................... 9
General preparation of shipments for transport ...................................................................................... 9
Basic triple packaging system................................................................................................................ 9
Packaging, labelling and documentation requirements for infectious substances in CategoryA....... 10
Packaging............................................................................................................................................. 10
Marking................................................................................................................................................ 12
Labelling.............................................................................................................................................. 12
Documentation..................................................................................................................................... 14
Packaging, labelling and documentation requirements for infectious substances in Category B....... 16
Packaging............................................................................................................................................. 16
Marking................................................................................................................................................ 17
Documentation..................................................................................................................................... 17
Overpacks.................................................................................................................................................. 18
Reusing packaging materials ................................................................................................................. 18
Shipping empty packagings.................................................................................................................... 18
Refrigerants .............................................................................................................................................. 18
Training..................................................................................................................................................... 19
Recommendations for countries that have not adopted the United Nations system............................ 20
Transportplanning ................................................................................................................................... 20
The shipper (sender, consignor)........................................................................................................... 20
The carrier............................................................................................................................................ 20
The receiver (consignee)...................................................................................................................... 21
Requirements for air mail ........................................................................................................................ 21
Spill clean-up procedure........................................................................................................................... 21
Incidentreporting..................................................................................................................................... 22
Annex 1 Additional information on the United Nations System for the Transport of Dangerous
Goods......................................................................................................................................................... 23
Annex 2 Examples of infectious substances included in CategoryA.................................................... 24
6. 2
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 3 PackingInstruction P620........................................................................................................... 26
Annex 4 Packing Instruction P650 .......................................................................................................... 28
Annex 5 List of dangerous goods related to the transport of infectioussubstances............................ 32
Annex 6 Special Provisions applicable to certain substances................................................................ 33
Annex 7 Flowchart for the classification of infectious substances and patient specimens.................. 35
7. 3
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Introduction
Infectious substances are transported for a variety of different reasons, within countries and across
international borders. It is incumbent upon shippers to ensure packaging and shipping conditions meet
regulatory requirements to preserve the integrity of materials, and facilitate their timely arrival at
destination.
Postal, airline and other transport industry personnel may have concerns about the possibility of
becoming infected as the result of exposure to infectious microorganisms that may escape from broken,
leaking or improperly packaged material. The packaging of infectious substances for transport must
therefore be designed to minimize the potential for damage during transport. In addition, the packaging must
ensure the integrity of the materials and so, in turn, timely and accurate processing of specimens.
The following guidelines provide information for classifying infectious substances for transportation and
ensuring their safe packaging. They stress the importance of developing a working relationship between
those involved – the sender, the carrier and the receiver – in order to provide for safe and expeditious
transport of these materials.
These guidelines provide practical guidance to facilitate compliance with applicable international
regulations for the transport of infectious substances and patient specimens by all modes of transport, both
nationally and internationally, and include the changes that apply from 1 January 2015. They replace
the guidelines issued by the World Health Organization (WHO) in 2013 (document
WHO/CDS/IHR/2012.12). This publication, however, does not replace national and international transport
regulations.
Today, thousands of samples of infectious substances need to be shipped and are shipped daily around the
world. Human and animal specimens are collected and shipped for a variety of reasons, including disease
investigations, clinical trials, surveillance studies, antidoping testing, routine analyses, etc. Regular and
occasional shippers consign infectious substances for transport on a daily basis. These include the
pharmaceutical industry, health care facilities, diagnostic and research laboratories, medical practitioners,
and individual patients.
In the interest of global public health, human and animal specimens need to be transported safely,
timely, efficiently and legally from the place where they are collected to the place where they will be
analyzed. Regardless of the presumed infection status of the patient, specimens of human and animal
origin should be packaged and transported in such a way as to protect those engaged in transportation from
the risk of infection. Risks of infection of personnel involved in transport may not be fully eliminated.
However, they can undoubtedly be kept to a minimum. In addition, damage to packaging also means that
samples dispatched for urgent tasks like analyses are unlikely to arrive to destination on time.
In order to make appropriate decisions, shippers must understand their need and obligation to be
familiar with regulatory requirements. Dangerous goods regulations require all personnel involved in
transport to undergo appropriate training. Appropriate training and education, commensurate with the
shipper's responsibilities, will provide the shipper with the necessary degree of familiarity with applicable
requirements, addressing identification, classification, packaging, marking, labelling, refrigeration and
required documentation for the transport of infectious substances.
This document will familiarize the reader with current international and modal requirements for the
shipment of infectious substances.
8. 4
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
International regulations
The international regulations for the transport of infectious substances by any mode of transport are
based upon the Recommendations made by the Committee of Experts on the Transport of Dangerous
Goods (UNCETDG), a committee of the United Nations Economic and Social Council. The
Recommendations are presented in the form of Model Regulations. The United Nations Model Regulations
are reflected in international law through international modal agreements (links to further information are
provided in Annex 1):
Air The Technical Instructions for the Safe Transport of Dangerous Goods by Air published by the
International Civil Aviation Organization (ICAO) are the legally binding international
regulations. The International Air Transport Association (IATA) publishes Dangerous Goods
Regulations (DGR) that incorporate the ICAO provisions and may add further restrictions
(where necessary such restrictions are included in these guidelines). The ICAO rules apply on all
international flights. For national flights, i.e. flights within one country, national civil aviation
authorities apply national legislation. This is normally based on the ICAO provisions, but may
incorporate variations. State and operator variations are published in the ICAO Technical
Instructions and in the IATA Dangerous Goods Regulations.
Rail Regulations concerning the International Carriage of Dangerous Goods by Rail (RID) apply to
countries in Europe, the Middle East and North Africa. RID also applies to domestic transport in
the European Union through Council Directive 2008/68/EC.
Road The European Agreement concerning the International Carriage of Dangerous Goods by Road
(ADR) applies to 48 countries. In addition, modified versions of the convention are being used by
countries in South America and South-East Asia. ADR also applies to domestic transport in the
European Union through Council Directive 2008/68/EC.
Sea The International Maritime Dangerous Goods Code published by the International Maritime
Organization (IMO) is of mandatory application for all contracting parties to the International
Convention for the Safety of Life at Sea (SOLAS).
Post The Letter post manual published by the Universal Postal Union (UPU) reflects the United
Nations Recommendations using the ICAO provisions as the basis for shipments.
The World Health Organization serves in an advisory capacity to UNCETDG and ICAO.
National regulations
Many countries adopt the United Nations Model Regulations in their entirety to stand as their national
dangerous goods legislation. Some countries apply variations. National authorities should provide
details of their own national requirements.
Note: These guidelines are based on the 18th revised edition of the United Nations Recommendations on
the Transport of Dangerous Goods, the text of which is reflected in the 2015 editions of the
international modal regulations (e.g. ICAO Technical Instructions for the Safe Transport of Dangerous
Goods by Air, Doc 9284 AN/905, 2015–2016 Edition; ADR, European Agreement Concerning the
International Carriage of Dangerous Goods by Road, applicable as from 1 January 2015) and in many sets
of national legislation. In December 2014, UNCETDG agreed on further changes for the 19th edition.
These changes do not come into force until 2017. If, in the future, further modifications are made to the
section of the United Nations Recommendations that deals with infectious substances and patient
specimens, the WHO guidelines will be updated accordingly.
9. 5
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Definitions
In describing transport safety measures, the terms “infectious substances” and “infectious materials”
are considered to be synonymous. The term “infectious substances” is used in this document. Text
reproduced from the United Nations Model Regulations is italicized.
Infectious substances
For the purposes of transport, infectious substances are defined as substances which are known or are
reasonably expected to contain pathogens. Pathogens are defined as microorganisms (including
bacteria, viruses, rickettsiae, parasites, fungi) and other agents such as prions, which can cause
disease in humans or animals. The definition is applied to all specimens except those explicitly
exempted (see below).
Cultures
Cultures are the result of a process by which pathogens are intentionally propagated. This definition
does not include human or animal patient specimens as defined below.
Patient specimens
Patient specimens are human or animal materials, collected directly from humans or animals,
including, but not limited to, excreta, secreta, blood and its components, tissue and tissue fluid swabs,
and body parts being transported for purposes such as research, diagnosis, investigational activities,
disease treatment and prevention.
Biological products
Biological products are those products derived from living organisms which are manufactured and
distributed in accordance with the requirements of appropriate national authorities, which may have
special licensing requirements, and are used either for prevention, treatment, or diagnosis of disease
in humans or animals, or for development, experimental or investigational purposes related thereto.
They include, but are not limited to, finished or unfinished products such as vaccines.
Genetically modified microorganisms (GMMOs) and organisms (GMOs) Genetically
modified microorganisms not meeting the definition of infectious substance are classified in Class 9
(Miscellaneous dangerous substances and articles, including environmentally hazardous substances).
GMMOs and GMOs are not subject to dangerous goods regulations when authorized for use by the
competent authorities of the countries of origin, transit and destination. Genetically modified live
animals shall be transported under terms and conditions of the competent authorities of the countries
of origin and destination.
Medical or clinical wastes
Medical or clinical wastes are wastes derived from the medical treatment of animals or humans or
from bio-research.
10. 6
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Classification
Dangerous goods are assigned UN numbers and proper shipping names according to their hazard
classification and their composition. Proper shipping names are used to clearly identify the dangerous
article or substance.
Infectious substances are classified in Division 6.2 and assigned to UN 2814, UN 2900, UN 3291 or
UN 3373, as appropriate.
Infectious substances are divided into the following categories:
Category A
An infectious substance which is transported in a form that, when exposure to it occurs, is capable of
causing permanent disability, life-threatening or fatal disease in otherwise healthy humans or animals.
Indicative examples of substances that meet these criteria are given in the table in Annex 2.
NOTE: An exposure occurs when an infectious substance is released outside of the protective
packaging, resulting in physical contact with humans or animals.
(a) Infectious substances meeting these criteria which cause disease in humans or both
in humans and animals shall be assigned to United Nations number UN 2814.
Infectious substances which cause disease only in animals shall be assigned to UN 2900.
(b) Assignment to UN 2814 or UN 2900 shall be based on the known medical history and
symptoms of the source human or animal, endemic local conditions, or professional
judgement concerning individual circumstances of the source human or animal.
NOTE 1: The proper shipping name for UN 2814 is INFECTIOUS SUBSTANCE,
AFFECTING HUMANS. The proper shipping name for UN 2900 is INFECTIOUS SUBSTANCE,
AFFECTING ANIMALS only.
NOTE 2: The table in Annex 2 is not exhaustive. Infectious substances, including new or
emerging pathogens, which do not appear in the table but which meet the same criteria shall be
assigned to Category A. In addition, if there is doubt as to whether or not a substance meets the
criteria it shall be included in Category A.
NOTE 3: In the table in Annex 2, the microorganisms written in italics are bacteria,
mycoplasmas, rickettsiae or fungi.
Category B
An infectious substance which does not meet the criteria for inclusion in Category A. Infectious
substances in Category B shall be assigned to UN 3373.
NOTE: The proper shipping name of UN 3373 is “BIOLOGICAL SUBSTANCE, CATEGORY B”.
Exemptions
Substances that do not contain infectious substances or that are unlikely to cause disease in humans or
animals are not subject to dangerous goods regulations, unless they meet the criteria for inclusion in
another class.
Substances containing microorganisms which are non-pathogenic to humans or animals are not subject
to dangerous goods regulations, unless they meet the criteria for inclusion in another class.
11. 7
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Substances in a form that any present pathogens have been neutralized or inactivated such that they
no longer pose a health risk are not subject to dangerous goods regulations, unless they meet the
criteria for inclusion in another class.
NOTE: Medical equipment which has been drained of free liquid is deemed to meet the
requirements of this paragraph and is not subject to dangerous goods regulations.
Environmental samples (including food and water samples) which are not considered to pose a
significant risk of infection are not subject to dangerous goods regulations, unless they meet
the criteria for inclusion in another class.
Dried blood spots, collected by applying a drop of blood onto absorbent material are not subject
to dangerous goods regulations.
Faecal occult blood screening samples are not subject to dangerous goods regulations.
Blood or blood components which have been collected for the purposes of transfusion or for
the preparation of blood products to be used for transfusion or transplantation and any tissues or
organs intended for use in transplantation as well as samples drawn in connection with such
purposes are not subject to dangerous goods regulations.
Human or animal specimens (patient specimens) for which there is minimal likelihood that pathogens
are present are not subject to dangerous goods regulations if the specimen is transported in a
packaging which will prevent any leakage and which is marked with the words “Exempt human
specimen” or “Exempt animal specimen”, as appropriate. The packaging should meet the following
conditions:
a) The packaging should consist of three components:
i) a leak-proof primary receptacle(s);
ii) a leak-proof secondary packaging; and
iii) an outer packaging of adequate strength for its capacity, mass and intended use,
and with at least one surface having minimum dimensions of 100 mm × 100 mm;
b) For liquids, absorbent material in sufficient quantity to absorb the entire contents should
be placed between the primary receptacle(s) and the secondary packaging so that, during
transport, any release or leak of a liquid substance will not reach the outer packaging and
will not compromise the integrity of the cushioning material;
c) When multiple fragile primary receptacles are placed in a single secondary packaging,
they should be either individually wrapped or separated to prevent contact between them.
NOTE 1: An element of professional judgment is required to determine if a substance is exempt
under this paragraph. That judgment should be based on the known medical history, symptoms
and individual circumstances of the source, human or animal, and endemic local conditions.
Examples of specimens which may be transported under this paragraph include the blood or
urine tests to monitor cholesterol levels, blood glucose levels, hormone levels, or prostate
specific antigen (PSA); those required to monitor organ function such as heart, liver or kidney
function for humans or animals with non-infectious diseases, or therapeutic drug monitoring;
those conducted for insurance or employment purposes and are intended to determine the
presence of drugs or alcohol; pregnancy test; biopsies to detect cancer; and antibody detection
in humans or animals in the absence of any concern for infection (e.g. evaluation of vaccine
induced immunity, diagnosis of autoimmune disease, etc.).
NOTE 2: For air transport, packagings for specimens exempted under this paragraph
shall meet the conditions in (a) to (c).
12. 8
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Except for:
(a) Medical waste (UN 3291);
(b) Medical devices or equipment contaminated with or containing infectious substances
in Category A (UN 2814 or UN 2900); and
(c) Medical devices or equipment contaminated with or containing other dangerous
goods that meet the definition of another hazard class,
medical devices or equipment potentially contaminated with or containing infectious substances
which are being transported for disinfection, cleaning, sterilization, repair, or equipment
evaluation are not subject to the provisions of dangerous goods regulations if packed in packagings
designed and constructed in such a way that, under normal conditions of transport, they cannot break,
be punctured or leak their contents. Packagings shall be designed to meet specific construction
requirements – this is not considered further in these guidelines.
These packagings shall meet general packaging requirements not considered further in these
guidelines, and be capable of retaining the medical devices and equipment when dropped from a
height of 1.2 m. For air transport, additional requirements may apply.
The packaging shall be marked “USED MEDICAL DEVICE” or “USED MEDICAL
EQUIPMENT”. When using overpacks, these shall be marked in the same way, except when
the inscription remains visible.
Biological products
For the purposes of transport, biological products are divided into two groups:
(a) those which are manufactured and packaged in accordance with the requirements
of appropriate national authorities and transported for the purposes of final packaging
or distribution, and use for personal health care by medical professionals or
individuals. Substances in this group are not subject to dangerous goods regulations;
(b) those which do not fall under paragraph (a) and are known or reasonably believed to
contain infectious substances and which meet the criteria for inclusion in Category A or
Category B. Substances in this group shall be assigned to UN 2814, UN 2900 or UN
3373, as appropriate.
NOTE: Some licensed biological products may present a biohazard only in certain parts of the world.
In that case, competent authorities may require these biological products to be in compliance with
local requirements for infectious substances or may impose other restrictions.
Genetically modified microorganisms and organisms
GMMOs or GMOs that do not meet the definition of toxic substances or infectious substances shall be
assigned to UN 3245. GMMOs and GMOs assigned to UN 3245 shall be shipped following
Packing Instruction P904 (ICAO/IATA PI959) – this is not considered further in these guidelines.
NOTE: The proper shipping name for UN 3245 is “GENETICALLY MODIFIED MICRO-
ORGANISMS” or "GENETICALLY MODIFIED ORGANISMS".
Medical or clinical wastes
Medical or clinical wastes containing Category A infectious substances shall be assigned to UN 2814
or UN 2900 as appropriate. Medical or clinical wastes containing infectious substances in Category B,
13. 9
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
or which are reasonably believed to have a low probability of containing infectious substances,
shall be assigned to UN 3291 and shipped following Packing Instruction P621 (ICAO/IATA PI622) –
this is not considered further in these guidelines. For the assignment, international, regional or
national waste catalogues may be taken into account.
NOTE: The proper shipping name for UN 3291 is “CLINICAL WASTE, UNSPECIFIED, N.O.S.”
or "(BIO) MEDICAL WASTE, N.O.S." or "REGULATED MEDICAL WASTE, N.O.S.".
Decontaminated medical or clinical wastes which previously contained infectious substances are
not subject to dangerous goods regulations unless they meet the criteria for inclusion in another class.
The bulk transport of wastes of Division 6.2 (UN 3291) is permitted according to provisions not further
considered in these guidelines.
Infected animals
Unless an infectious substance cannot be consigned by any other means, live animals shall not be
used to consign such a substance. A live animal which has been intentionally infected and is known
or suspected to contain an infectious substance shall only be transported under terms and
conditions approved by the competent authority.
Animal material affected by pathogens of Category A or which could be assigned to Category A
in cultures only, shall be assigned to UN 2814 or UN 2900 as appropriate. Animal material
affected by pathogens of Category B other than those which would be assigned to Category A if
they were in cultures shall be assigned to UN 3373.
The bulk transport of animal material containing infectious substances (UN 2814, 2900 and 3373) is
authorized according to provisions not further considered in these guidelines.
General preparation of shipments for transport
Because of the differences in the hazards posed by Category A infectious substances (UN 2814
and UN 2900) and Category B infectious substances (UN 3373), there are variations in the
packaging, labelling and documentation requirements for the two categories. The packaging
requirements are determined by UNCETDG and are set out as Packing Instructions P620 and
P650, reproduced in Annexes 3 and 4, respectively. The requirements are subject to change and
regular upgrade by the organizations mentioned. The current packaging requirements are described
below.
Note 1: Hand carriage of Category A and Category B infectious substances and transport of these
materials in diplomatic pouches are strictly prohibited by international air carriers.
Note 2: Inner packagings containing infectious substances shall not be consolidated with inner
packagings containing unrelated types of goods.
Shippers of infectious substances shall ensure that packages are prepared in such a manner that they
arrive at their destination in good condition and present no hazard to persons or animals
during transport.
Basic triple packaging system
This system of packaging shall be used for all infectious substances. It consists of three layers as
follows:
14. 10
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Primary receptacle. A primary watertight, leak-proof receptacle containing the specimen. The
receptacle is packaged with enough absorbent material to absorb all fluid in case of breakage or
leakage.
Secondary packaging. A second durable, watertight, leak-proof packaging to enclose and protect the
primary receptacle(s). Several cushioned primary receptacles may be placed in one secondary
packaging, but sufficient additional absorbent material shall be used to absorb all fluid in case of
breakage or leakage.
Outer packaging. Secondary packagings are placed in outer shipping packagings with suitable
cushioning material. Outer packagings protect their contents from outside influences, such as
physical damage, while in transit. The smallest overall external dimension shall be 10 x 10 cm.
Each completed package is normally required to be correctly marked, labelled and accompanied
with appropriate shipping documents (as applicable). The requirements for these aspects are
described below.
Packaging, labelling and documentation requirements for
infectious substances in Category A
Packaging
Infectious substances in Category A may only be transported in packaging that meets the United
Nations class 6.2 specifications and complies with Packing Instruction P620 (see Annex 3; Figure 1).
This ensures that strict performance criteria are met; tests for compliance with these criteria include a
9-metre drop test, a puncture test, a pressure test and a stacking test. The outer packaging shall bear the
United Nations packaging specification marking (Figure 2), which indicates that the packaging has
passed the performance tests to the satisfaction of the competent authority.
The primary receptacle or the secondary packaging shall be capable of withstanding a pressure
differential of not less than 95 kPa. The United Nations packaging specification marking alone
does not indicate that a test for this has been undertaken, and packaging users should ask their
suppliers whether the completed package meets this requirement.
There is no comprehensive list of suppliers of packagings that comply with Packing Instruction P620.
However, an Internet search using a suitable international or national search engine usually provides
appropriate information, as well as access to national regulations. Search phrases such as “UN
packaging” and “UN infectious substance packaging” produce extensive results. Carriers and
forwarding agents should also be able to supply details of local suppliers or local companies that can
provide such information.
15. 11
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Figure 1. Example of triple packaging system for the packaging and labelling of Category A infectious
substances (Figure kindly provided by IATA, Montreal, Canada)
u
n 4G/Class 6.2/10/GB/2470
This marking comprises:
• the United Nations packaging symbol
• an indication of the type of packaging (in this example a
fibreboard box (4G))
• an indication that the packaging has been specially
tested to ensure that it meets the requirements for Category A
infectious substances (Class 6.2)
• the last two digits of the year of manufacture (in this
example 2010)
• the competent state authority that has authorized the
allocation of the mark (in this example GB, signifying Great
Britain)
• the manufacturer’s code specified by the competent
authority (in this example 2470)
Users shall be provided with clear instructions as to how the package
should be filled and prepared for transport.
Figure 2. UN specification marking for Category A infectious substances (UN 2814 and UN 2900)
For surface transport there is no maximum quantity per package. For air transport the limits per
package are as follows:
• 50 ml or 50 g for passenger aircraft
• 4 litres or 4 kg for cargo aircraft.
Any primary receptacle with a capacity of more than 50 ml shall be oriented in the outer packaging so
that the closures are upwards. Orientation labels (“UP” arrows) shall be affixed to two opposite sides
of the outer packaging.
16. 12
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Marking
Packages are marked to provide information about the contents of the package, the nature of the hazard,
and the packaging standards applied. All markings on packages or overpacks shall be placed in such a
way that they are clearly visible and not covered by any other label or marking. Each package shall
display the following information on the outer packaging or the overpack.
• the shipper’s (sender’s, consignor’s) name and address
• the telephone number of a responsible person, knowledgeable about the shipment
• the receiver’s (consignee’s) name and address
• the United Nations number followed by the proper shipping name (UN 2814 “INFECTIOUS
SUBSTANCE, AFFECTING HUMANS” or UN 2900 “INFECTIOUS SUBSTANCE, AFFECTING
ANIMALS only”, as appropriate). Technical names need not be shown on the package.
• temperature storage requirements (optional)
• when dry ice or liquid nitrogen is used: the technical name of the refrigerant, the appropriate
United Nations number, and the net quantity.
Labelling
There are two types of labels: (a) hazard labels in the form of a square set at an angle of 45° (diamond-
shaped) are required for most dangerous goods in all classes; (b) handling labels in various shapes are
required, either alone or in addition to hazard labels, for some dangerous goods. Specific hazard label(s)
shall be affixed to the outside of each package for all dangerous goods to be shipped (unless
specifically exempted). The hazard labels shown in Figures 3–5 and handling labels in Figures 6
and 7 are of importance for infectious substances in Category A:
Label name: Infectious substance
Minimum dimensions: 100 × 100 mm
(for small packages: 50 × 50 mm) No. of
labels per package: 1
Colour: Black and white
The words “INFECTIOUS SUBSTANCE” shall be shown. The
statement “In case of damage or leakage immediately notify a
Public Health Authority” is required in some countries.
Figure 3. Hazard label for Category A infectious substances and for genetically modified
microorganisms and organisms that meet the definition of an infectious substance, Category A
Label name: Miscellaneous dangerous substances
Minimum dimensions: 100 × 100 mm
(for small packages: 50 × 50 mm) No. of
labels per package: 1
Colour: Black and white
Figure 4. Hazard label for certain noninfectious genetically modified microorganisms and organisms
(UN 3245) and for carbon dioxide, solid (dry ice) (UN 1845); substances packed in dry ice (see section
on Refrigerants) shall bear this label in addition to the primary risk label (e.g. the label shown in
17. 13
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Figure 3 for Category A infectious substances, the marking shown in Figure 10 for Category B
infectious substances)
Label name: Non flammable, non-toxic gas
Minimum dimensions: 100 × 100 mm
(for small packages: 50 × 50 mm) No. of
labels per package: 1
Colour: Green and white or green and black
Figure 5. Hazard label for liquid nitrogen; substances packed using liquid nitrogen (see section on
Refrigerants) shall bear this label in addition to the primary risk label (e.g. the label shown in Figure 3
for Category A infectious substances, the marking shown in Figure 10 for Category B infectious
substances)
Label name: Cryogenic liquid
Minimum dimensions: Standard A7: 74 × 105 mm
No. of labels per package: 1
Colour: Green and white
Figure 6. Handling label for cryogenic liquids; for transport by air, where cryogenic liquids (deeply
refrigerated liquefied gases) are used (see section on Refrigerants), this label shall be affixed to
insulated vessels or flasks used as outer packaging in addition to the labels or markings shown in
Figures 3, 5 and 10, as appropriate
Label name: Orientation label
Minimum dimensions: Standard A7: 74 × 105 mm
No. per package: 2 on opposite sides
Colour: Black and white or red and white
The words “THIS SIDE UP” or “THIS END UP” may also be
displayed on the top cover of the package.
Figure 7. Orientation label to indicate position of closures on the primary receptacles; for the air
transport of quantities of liquid infectious substances in Category A that exceed 50 ml per primary
receptacle, this label shall be affixed to two opposite sides of the package with the arrows pointing in
the right direction, in addition to the label shown in Figure 3
Instructions for the labelling of overpacks are given in the section on Overpacks.
18. 14
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Documentation
The following shipping documents are required.
To be prepared and signed by the shipper:
• for air: the shipper’s Declaration for Dangerous Goods (Figure 8 shows an example)
• a packing list/proforma invoice that includes the receiver’s address, the number of packages,
detail of contents, weight, value (Note: for international transport, a minimal value shall be
indicated, for customs purposes, if the items are supplied free of charge)
• an import and/or export permit and/or declaration if required
To be prepared by the shipper or the shipper’s agent:
• an air waybill for air transport or equivalent documents for road, rail and sea shipments.
For UN 2814 and UN 2900, an itemized list of contents shall be enclosed between the secondary
packaging and the outer packaging.
For the purposes of documentation, the proper shipping name shall be supplemented with the technical
name. Technical names need not be shown on the package. When the infectious substances to be
transported are unknown, but suspected of meeting the criteria for inclusion in category A and
assignment to UN 2814 or UN 2900, the words “suspected Category A infectious substance” shall be
shown, in parentheses, following the proper shipping name on the transport document, but not on the
outer packagings.
19. 15
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Figure 8. Example of a completed shipper’s Declaration for Dangerous Goods
20. 16
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Packaging, labelling and documentation requirements for
infectious substances in Category B
Packaging
The triple packaging system continues to apply, including for local surface transport. Testing
documents are not required, however. It may be possible to source packagings locally rather than
finding an authorized supplier, provided that the packaging manufacturer and the shipper can comply
fully with the requirements of P650 (see Annex 4; Figure 9).
As for P620, there is no comprehensive list of suppliers of packagings that comply with Packing
Instruction P650. However, an Internet search using a suitable international or national search engine
usually provides appropriate information, as well as access to national regulations. Search phrases such
as “UN packaging” and “UN infectious substance packaging” produce extensive results. Carriers and
forwarding agents should also be able to supply details of local suppliers or local companies that can
provide such information.
To ensure correct preparation for transport, packaging manufacturers and subsequent distributors shall
provide clear instructions to the consignor or persons preparing packages (e.g. patients) on how the
packaging should be filled and closed.
For surface transport there is no maximum quantity per package. For air transport:
• no primary receptacle shall exceed 1 litre and the outer packaging must not contain more than
4 litres(for liquids)
• except for packages containing body parts, organs or whole bodies, the outer packaging must not
contain more than 4 kg (for solids).
Figure 9. Example of the triple packaging system for the packing and labelling of Category B
infectious substances (Figure kindly provided by IATA, Montreal, Canada)
21. 17
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Provided all the requirements of P650 are met, there are no other transport requirements. P650
incorporates all that is needed to make a shipment for Category B infectious substances.
Marking
Each package shall display the following information:
• for air: the shipper’s (sender’s, consignor’s) name, address and telephone number
• for air: the telephone number of a responsible person, knowledgeable about the shipment
• the receiver’s (consignee’s) name, address and telephone number
• the proper shipping name (“BIOLOGICAL SUBSTANCE, CATEGORY B”) adjacent to
the diamond-shaped mark shown in Figure 10
• temperature storage requirements (optional).
The marking shown in Figure 10 is used for shipments of Category B infectious substances.
Figure 10. Marking for infectious substances of Category B
Note: For air transport:
• when dry ice (solid carbon dioxide) is used (see section on Refrigerants), the label shown in
Figure 4 shall be applied
• for cryogenic liquids (see section on Refrigerants) the labels shown in Figures 5 and 6 shall also
be affixed.
Documentation
Dangerous goods documentation (including a shipper’s declaration) is not required for Category B
infectious substances. The following shipping documents are required.
To be prepared and signed by the shipper (sender, consignor):
• for international shipments: a packing list/proforma invoice that includes the shipper's and
the receiver’s address, the number of packages, detail of contents, weight, value (Note: the
statement “no commercial value” shall appear if the items are supplied free of charge)
• an import and/or export permit and/or declaration if required.
To be prepared by the shipper or the shipper’s agent:
• an air waybill for air transport or equivalent documents for road, rail and sea journeys.
• Minimum dimension: the width of the line forming the
square shall be at least 2 mm, and the letters and numbers
shall be at least 6 mm high. For air transport, each side of
the square shall have a length of at least 50 mm
• Colour: none specified, provided the mark is displayed on
the external surface of the outer packaging on a background
of contrasting colour and that it is clearly visible and legible
• The words “BIOLOGICAL SUBSTANCE, CATEGORY
B” in letters at least 6 mm high shall be displayed adjacent
to the mark.
22. 18
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
A flowchart to help with the classification of infectious substances and patient specimens is shown in
Annex 7.
Overpacks
"Overpack" is the term used when several packages are combined to form one unit and sent to the same
destination by a single shipper. When refrigerants are used to protect contents, the overpacks may
comprise insulated vessels or flasks. Whenever an overpack is used, the required marks and labels
shown on the outer packaging must be repeated on the outermost layer of the overpack. This
requirement applies to infectious substances in Categories A and B. Overpacks are also required to be
marked with the word “overpack”.
NOTE: Do not reproduce the UN specification marking on the overpack.
Reusing packaging materials
Shipping packages can be reused. If shippers plan on reusing a package, it must be appropriately
disinfected. Before reusing a package, the shipper must make sure all markings and labels reflect the
substances actually being shipped. If the shipper plans on shipping an empty package, all non-
applicable markings and labels must be removed or covered.
Shipping empty packagings
Before an empty package is returned to the shipper, or sent elsewhere, it must be appropriately
disinfected or sterilized to nullify any hazard. Any label or marking indicating that it had contained an
infectious substance shall be removed or covered.
Refrigerants
Refrigerants may be used to stabilize infectious substances in Categories A and B during transit.
Packed infectious substances requiring cooling assigned to packing instructions P620 or P650 shall
meet the appropriate requirements of that packing instruction.
Ice, ice pads or dry ice shall be placed outside the secondary receptacle or in an outer packaging or in
an overpack. Wet ice shall be placed in a leak-proof container; the outer packaging or overpack shall
also be leak-proof. Dry ice must not be placed inside the primary or secondary receptacle because of
the risk of explosions. A specially designed insulated packaging may be used to contain dry ice. The
packaging must permit the release of carbon dioxide gas if dry ice is used. Packing instruction P003
(ICAO/IATA PI954) shall be observed.
The secondary receptacle shall be secured within the outer package to maintain the original orientation
of the inner packages after the refrigerant has melted or dissipated.
23. 19
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
If dry ice is used to ship infectious substances in Category A, the details shall appear on the shipper’s
Declaration for Dangerous Goods. If dry ice is used to ship infectious substances in Category B or
Exempt samples, the shipper’s Declaration of Dangerous Goods is not required. In any case, the
outermost packaging shall carry the hazard label for dry ice (see Figure 4), the appropriate markings,
including the UN number and the proper shipping name followed by the words “AS COOLANT”, for
example: UN 1845, CARBON DIOXIDE,SOLID, AS COOLANT. and an indication of the net
quantity of dry ice in kilograms.
If liquid nitrogen is used as a refrigerant, special arrangements shall be made in advance with the
carrier. Primary receptacles shall be capable of withstanding extremely low temperatures, and
packaging and documentation requirements for liquid nitrogen shall be observed. In particular, the
outermost packaging shall carry the hazard label for liquid nitrogen (see Figure 5). For air transport,
the handling label for cryogenic liquids shall also be affixed (see Figure 6) – this is not considered
further in these guidelines.
When shipping with liquid nitrogen, "dry shippers" can be used. Correctly prepared "dry shippers" do
not contain free liquid nitrogen. While liquid nitrogen is a regulated dangerous good, a properly
prepared "dry shipper" is not. When shipping with "dry shippers", the dangerous goods label for class 2
(non-flammable, non-toxic gases) is NOT required. Shippers must properly mark and label the outside
of dry shipper packages containing infectious substances. Appropriate documentation should discuss
the presence of infectious substances. For Category A this information will be included in the
Dangerous Goods Declaration. For Category B and Exempt packages this information should be
provided on the Air Waybill.
Training
The dangerous goods regulations require all personnel involved in transport to undergo appropriate
training.
For the transport of Category A infectious substances, personnel must undergo training in accordance
with the modal requirements. This can involve attendance at approved courses and passing
examinations.
For the transport of Category B infectious substances there is a requirement that clear instructions on
the use of the packaging are supplied to the user; this is regarded as sufficient “training” for the
shipping of these substances. However, if such specimens are consigned with other dangerous goods
(e.g. flammable liquids, radioactive materials, liquefied gases, etc.), then personnel must be trained in
the proper procedures for their transport.
Training and awareness are important for all personnel involved in the transport of Category B
infectious substances. Training of personnel, for example via consultation of guidance documents like
this one, while not formally required by the modal regulations, is recommended and encouraged. Only
through appropriate guidance and training can shippers ensure that the classification of the substance to
be shipped is correct, and that proper packaging is selected and prepared. Carriers and other employers
of transport workers should train their personnel in the appropriate procedures for recognizing and
handling packages containing infectious substances and in how to address spills and protect themselves
from exposure.
Records of training received shall be kept by the employer and made available to the employee or
competent authority, upon request. Records shall be kept by the employer for a period of time
established by the competent authority. The training mentioned above shall be provided or verified
upon employment in a position involving the transport of infectious substances and shall be periodically
supplemented with retraining as deemed appropriate by the competent authority.
24. 20
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Recommendations for countries that have not adopted
the United Nations system
The recommendations set out above apply wherever the United Nations system for the transport of
infectious substances has been adopted. WHO encourages all countries to adopt this system, and
recommends those that have not yet done so to follow its provisions. However, the principles described
above are not intended to supersede national or local requirements.
Transport planning
It is the responsibility of the shipper to ensure the correct classification, packaging, labelling, and
documentation of all infectious substances destined for transport.
The efficient transport and transfer of infectious substances requires good coordination between the
sender, the carrier and the receiver to ensure that the material is transported safely and arrives on time
and in good condition. Such coordination depends upon well-established communications and a good
working relationship between the three parties.
The carriage of any goods whether dangerous or not, is a commercial matter for a carrier. The dangerous
goods rules described in these guidelines reflect governmental legal requirements. Indeed, different
countries may have adopted State variations to the United Nations Model Regulations. In addition, a
carrier that does not wish to carry particular goods is under no legal obligation to do so. Many carriers
(airlines, haulers and shipping lines) are “private carriers” and have the right to refuse to carry goods or
add additional requirements. In recent years it has become clear that some carriers are indeed refusing to
carry certain goods or are adding extra conditions. Provided such conditions do not conflict with the legal
requirements, this type of action is not illegal.
ICAO and IATA list the main carrier restrictions in force among airlines. Some airlines will not carry
dangerous goods at all, while others will carry only a very limited range of goods. As carrier restrictions
for the different modes of transport are not published centrally, harmonization between stakeholders is
essential. The shipper (sender, consignor), carrier and the receiver (consignee) have specific
responsibilities in ensuring successful transportation.
The shipper (sender, consignor)
• Makes advance arrangements with the receiver including investigating the need for import/export
permits
• Makes advance arrangements with the carrier to ensure:
o that the shipment will be accepted for appropriate transport
o that the shipment (direct transport if possible) is undertaken by the most direct routing
• Prepares necessary documentation, including permits, dispatch and shipping documents
• Notifies the receiver of transportation arrangements once these have been made, well in advance
of the expected arrival time.
The carrier
• Provides advice to the sender regarding the necessary shipping documents and instructions
for their completion
• Provides advice to the sender about correct packaging
• Assists the sender in arranging the most direct routing and then confirms the routing
• Maintains and archives the documentation for shipment and transport.
25. 21
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
The receiver (consignee)
• Obtains the necessary authorization(s) from national authorities for the importation of the material
• Provides the sender with the required import permit(s), letter(s) of authorization, or other
document(s) required by the national authorities
• Arranges for the most timely and efficient collection on arrival
• Should acknowledge receipt to the sender.
Shipments should not be dispatched until:
• Advance arrangements have been made between the sender, carrier and receiver
• The shipper has confirmed with the national authorities that the material may be legally exported
• The receiver has confirmed with the national authorities that the material may be legally imported
• The receiver has confirmed that there will be no delay incurred in the delivery of the package
to its destination.
Requirements for air mail
Infectious substances in Category A will not be accepted for shipment through postal services.
Infectious substances in Category B may be shipped by registered air mail, and the Universal Postal
Union recommends the following procedure.
The basic triple packaging system is used with the same requirements as for other means of transport.
The address label shall display the word “Lettre” or “Letter” and the green Customs Declaration Label
for Postal Mail is required for international mailing. “BIOLOGICAL SUBSTANCE, CATEGORY B”
shall be identified with the white diamond label with black letters “UN 3373” (see Figure 10).
Local/international restrictions may be in force. Prior contact should therefore be made with the
national public operator to ascertain whether the packaged material will be accepted by the postal
service in question.
Spill clean-up procedure
The appropriate response in the event of exposure to any infectious substance is to wash or disinfect
the affected area as soon as possible, regardless of the agent. Even if an infectious substance comes
into contact with non-intact skin, washing of the affected area with soap and water or with an antiseptic
solution can reduce the risk of infection. Medical advice should be obtained any time there is a
suspected exposure to infectious substances resulting from a damaged package. The following
procedure for clean-up can be used for spills of all infectious substances including blood. The person
must be trained on such procedure before performing these steps:
1. Wear gloves and protecting clothing, including face and eye protection if indicated.
2. Cover the spill with a cloth or paper towels to contain it.
3. Pour an appropriate disinfectant over the cloth or paper towels and the immediately surrounding area
(5% bleach solutions are generally appropriate, but for spills on aircraft, quaternary ammonium
disinfectants should be used).
26. 22
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
4. Apply the disinfectant concentrically beginning at the outer margin of the spill area, working
towards the centre.
5. After about 30 min, clear away the materials. If there is broken glass or other sharps are involved,
use a dustpan or a piece of stiff cardboard to collect the materials and deposit them into a puncture-
resistant container for disposal.
6. Clean and disinfect the area of the spillage (if necessary, repeat steps 2–5).
7. Dispose of contaminated materials into a leak-proof, puncture-resistant waste disposal container.
8. After successful disinfection, report the incident to the competent authority and inform them that
the site has been decontaminated (see Incident reporting below).
Detailed information on disinfectants and their recommended use can be found in Laboratory biosafety
manual, 3rd ed., Geneva, World Health Organization, 2004.
Incident reporting
No reports of infections resulting from transport-related exposures have been documented other than
the anthrax letters of 2001 in the USA. There have been reports of the transmission of acute respiratory
infections and tuberculosis associated with air travel, but these were attributed to direct person-to-
person contact and not to packaging problems or shipping incidents.
Statistical data collected by a group of central laboratories showed the efficacy of packaging compliant
with P650 and P620 in assuring that infectious substances are transported without leakage and loss of
materials. For the 4.92 million primary containers shipped in 2003 to any of the worldwide regional
offices of these central laboratories, just 106 breakages, 0.002% of the total number, were recorded.
Moreover, the leakages that did occur were all contained by the absorbent material, and no damage to
secondary containers or outer packagings was reported.
The various international modal regulations require the reporting of incidents to the relevant competent
transport authorities in addition to the necessary health authorities. This applies to both categories of
infectious substances, but particularly to those in Category A.
27. 23
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 1
Additional information on the United Nations System for the
Transport of Dangerous Goods
The United Nations dangerous goods web site provides comprehensive detail concerning the United
Nations Recommendations on the Transport of Dangerous Goods. It also provides links to the modal
agencies:
http://www.unece.org/trans/danger/danger.htm
The site below provides the full text of the United Nations Recommendations, which can be
downloaded in PDF format. Readers wishing to see the text relating to the transport of infectious
substances should download Part 2, Part 4 and Part 5 and Chapter 6.3 as downloadable text (It covers
construction and performance requirements for packagings intended to contain infectious substances)
of the Recommendations:
http://www.unece.org/trans/danger/publi/unrec/rev18/18files_e.html
The site below provides the full text of the European Agreement concerning the International Carriage of
Dangerous Goods by Road (ADR) of 2015.
http://www.unece.org/trans/danger/publi/adr/adr2015/15contentse.html
The amendments to ADR which come into force on 1 January 2015 may be found on the same site at:
http://www.unece.org/trans/danger/publi/adr/adr2013_amend.html
All these texts may be downloaded in PDF format. Readers wishing to study the text relating to the
transport of infectious substances should download Part 1 (Chapters 1.3, 1.4 and 1.10), Part 2 (section
2.2.62), Part 4 (Chapter 4.1, including section 4.1.4.1 packing instructions P620 and P650 (or, for
medical waste P621, IBC620 and LP620), and section 4.1.8), Part 5 and Part 6 (Chapter 6.3). Some
provisions in Parts 7 and 8 have also to be complied with for the transport operation.
Contracting parties to the various conventions for the transport of dangerous goods can be found on a
number of web sites:
Air ICAO: http://www.icao.int/safety/DangerousGoods/Pages/technical-
instructions.aspx (accessed 24 November 2014) and
http://www.icao.int/safety/DangerousGoods/Pages/StateVariationPage.aspx
Rail RID: http://www.otif.org/. RID is primarily for the countries of Europe, North Africa and
the Middle East. There are a number of countries (mainly Eastern Europe and Asia that apply RID
through the Organization for Cooperation of Railways (OSJD); details of RID membership can be
found at http://www.otif.org/en/about-otif/addresses-and-useful-links/member-states.html. Regulations
concerning the International Carriage of Dangerous Goods by Rail (RID) can be found in this
link: http://www.otif.org/en/publications/rid-2015.html
Road ADR:http://www.unece.org/trans/danger/publi/adr/country-info_e.htm (lists competent
authorities)
Sea IMO: http://www.imo.org
Post UPU: http://www.upu.int/
28. 1
For surface transport (ADR) nevertheless, when the cultures are intended for diagnostic or clinical
purposes, they may be classified as infectious substances of Category B.
24
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 2
Examples of infectious substances included in Category A
The table provided below is an indicative list taken from the 18th edition of the United Nations Model
Regulations. In this table, the microorganisms written in italics are bacteria, mycoplasmas, rickettsiae
or fungi.
INDICATIVE EXAMPLES OF INFECTIOUS SUBSTANCES INCLUDED IN CATEGORY A IN
ANY FORM UNLESS OTHERWISE INDICATED
UN Number and
Proper Shipping
Name
Microorganism
UN 2814
Infectious
substance,
affecting humans
Bacillus anthracis (cultures only)
Brucella abortus (cultures only)
Brucella melitensis (cultures only)
Brucella suis (cultures only)
Burkholderia mallei – Pseudomonas mallei – glanders (cultures only)
Burkholderia pseudomallei – Pseudomonas pseudomallei (cultures only)
Chlamydia psittaci – avian strains (cultures only)
Clostridium botulinum (cultures only)
Coccidioides immitis (cultures only)
Coxiella burnetii (cultures only)
Crimean-Congo haemorrhagic fever virus
Dengue virus (cultures only)
Eastern equine encephalitis virus (cultures only)
Escherichia coli, verotoxigenic (cultures only)1
Ebola virus
Flexal virus
Francisella tularensis (cultures only)
Guanarito virus
Hantaan virus
Hantaviruses causing haemorrhagic fever with renal syndrome
Hendra virus
Hepatitis B virus (cultures only)
Herpes B virus (cultures only)
Human immunodeficiency virus (cultures only)
Highly pathogenic avian influenza virus (cultures only)
Japanese Encephalitis virus (cultures only)
Junin virus
Kyasanur Forest disease virus
Lassa virus
Machupo virus
Marburg virus
Monkeypox virus
Mycobacterium tuberculosis (cultures only)1
Nipah virus
Continued on next page
29. 1
For surface transport (ADR) nevertheless, when the cultures are intended for diagnostic or clinical
purposes, they may be classified as infectious substances of Category B.
25
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
INDICATIVE EXAMPLES OF INFECTIOUS SUBSTANCES INCLUDED IN CATEGORY A IN
ANY FORM UNLESS OTHERWISE INDICATED
Omsk haemorrhagic fever virus
Poliovirus (cultures only)
Rabies virus (cultures only)
Rickettsia prowazekii (cultures only)
Rickettsia rickettsii (cultures only)
Rift Valley fever virus (cultures only)
Russian spring-summer encephalitis virus (cultures only)
Sabia virus
Shigella dysenteriae type 1 (cultures only)1
Tick-borne encephalitis virus (cultures only)
Variola virus
Venezuelan equine encephalitis virus (cultures only)
West Nile virus (cultures only)
Yellow fever virus (cultures only)
Yersinia pestis (cultures only)
UN 2900
Infectious
substance,
affecting animals
only
African swine fever virus (cultures only)
Avian paramyxovirus Type 1 – Velogenic Newcastle disease virus (cultures only)
Classical swine fever virus (cultures only)
Foot and mouth disease virus (cultures only)
Lumpy skin disease virus (cultures only)
Mycoplasma mycoides – contagious bovine pleuropneumonia (cultures only)
Peste des petits ruminants virus (cultures only)
Rinderpest virus (cultures only)
Sheep-pox virus (cultures only)
Goatpox virus (cultures only)
Swine vesicular disease virus (cultures only)
Vesicular stomatitis virus (cultures only)
30. 26
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 3
Packing Instruction P620
Infectious substances in Category A and designated as UN 2814 or UN 2900 may only be transported
in packaging that meets the United Nations class 6.2 specifications and complies with Packing
Instruction P620, which is reproduced below. The various provisions mentioned are set out in the
United Nations Model Regulations.
NOTE: Variations applying to air transport are highlighted in grey.
P620 PACKINGINSTRUCTION P620
This instruction applies to UN 2814 and UN 2900.
The following packagings are authorized provided the special packing provisions described below are met:
Packagings meeting the requirements of Chapter 6.3 and approved accordingly consisting of:
(a) Inner packagings comprising:
(i) leakproof primary receptacle(s);
(ii) a leakproof secondary packaging;
(iii) other than for solid infectious substances, an absorbent material in sufficient quantity to absorb the
entire contents placed between the primary receptacle(s) and the secondary packaging; if multiple
fragile primary receptacles are placed in a single secondary packaging, they shall be either
individually wrapped or separated so as to prevent contact between them;
(b) A rigid outer packaging.
Drums (1A1, 1A2, 1B1, 1B2, 1N1, 1N2, 1H1, 1H2, 1D, 1G);
Boxes (4A, 4B, 4N, 4C1, 4C2, 4D, 4F, 4G, 4H1, 4H2); Jerricans
(3A1, 3A2, 3B1, 3B2, 3H1, 3H2).
The smallest external dimension shall be not less than 100 mm (4 in).
Additionalrequirements:
1. Inner packagings containing infectious substances shall not be consolidated with inner packagings
containing unrelated types of goods. Complete packages may be overpacked in accordance with the
provisions of 1.2.1 and 5.1.2; such an overpack may contain dry ice.
2. Other than for exceptional consignments, e.g. whole organs which require special packaging, the
following additional requirements shall apply:
(a) Substances consigned at ambient temperatures or at a higher temperature. Primary receptacles
shall be of glass, metal or plastics. Positive means of ensuring a leakproof seal shall be provided,
e.g. a heat seal, a skirted stopper or a metal crimp seal. If screw caps are used, they shall be
secured by positive means, e.g., tape, paraffin sealing tape or manufactured locking closure;
(b) Substances consigned refrigerated or frozen. Ice, dry ice or other refrigerant shall be placed around
the secondary packaging(s) or alternatively in an overpack with one or more complete packages
marked in accordance with 6.3.3. Interior supports shall be provided to secure secondary
packaging(s) or packages in position after the ice or dry ice has dissipated. If ice is used, the outer
packaging or overpack shall be leakproof. If dry ice is used, the outer packaging or overpack shall
permit the release of carbon dioxide gas. The primary receptacle and the secondary packaging
shall maintain their integrity at the temperature of the refrigerant used;
(c) Substances consigned in liquid nitrogen. Plastics primary receptacles capable of withstanding very
low temperature shall be used. The secondary packaging shall also be capable of withstanding
very low temperatures, and in most cases will need to be fitted over the primary receptacle
individually. Provisions for the consignment of liquid nitrogen shall also be fulfilled. The primary
receptacle and the secondary packaging shall maintain their integrity at the temperature of the
liquid nitrogen;
(d) Lyophilized substances may also be transported in primary receptacles that are flame-sealed glass
ampoules or rubber-stoppered glass vials fitted with metal seals.
Continued on next page
31. 27
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
3. Whatever the intended temperature of the consignment, the primary receptacle or the secondary
packaging shall be capable of withstanding without leakage an internal pressure producing a pressure
differential of not less than 95 kPa and temperatures in the range -40 °C to +55 °C (-40 °F to +130 °F).
4. Other dangerous goods shall not be packed in the same packaging as Division 6.2 infectious substances
unless they are necessary for maintaining the viability, stabilizing or preventing degradation or
neutralizing the hazards of the infectious substances. A quantity of 30 ml or less of dangerous goods
included in Classes 3 (flammable liquids), 8 (corrosive substances) or 9 (miscellaneous dangerous
substances and articles, including environmentally hazardous substances) may be packed in each primary
receptacle containing infectious substances. These small quantities of dangerous goods of Classes 3, 8 or 9
are not subject to any additional requirements of these Regulations when packed in accordance with this
packing instruction.
5. Alternative packagings for the transport of animal material may be authorized by the competent authority
in accordance with the provisions of 4.1.3.7.
Special packing provisions
1. Shippers of infectious substances shall ensure that packages are prepared in such a manner that they
arrive at their destination in good condition and present no hazard to persons or animals during transport.
2. An itemized list of contents shall be enclosed between the secondary packaging and the outer packaging,
When the infectious substances to be transported are unknown, but suspected of meeting the criteria for
inclusion in category A, the words "suspected category A infectious substance" shall be shown, in
parenthesis, following the proper shipping name on the document inside the outer packaging.
3. Before an empty packaging is returned to the shipper, or sent elsewhere, it must be disinfected or
sterilized to nullify any hazard and any label or marking indicating that it had contained an infectious
substance must be removed or obliterated.
32. Continued on next page
28
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 4
Packing Instruction P650
The text of United Nations Packing Instruction P650, in use for the transport of infectious substances in
category B assigned to UN 3373 by all surface modes of transport is reproduced below. The shaded text
on the right hand side indicates the ICAO variations to these instructions that apply to the transport by
air. The various provisions mentioned are set out in the United Nations Model Regulations.
NOTE: Variations applying to air transport are displayed on a grey background.
P650 PACKING INSTRUCTION P650
This packing instruction applies to UN 3373 on passenger and cargo aircraft, and cargo aircraft only
(CAO).
(1) The packaging shall be of good quality, strong enough to withstand the shocks and loadings normally
encountered during transport, including trans-shipment between cargo transport units and between transport
units and warehouses as well as any removal from a pallet or overpack for subsequent manual or
mechanical handling. Packagings shall be constructed and closed to prevent any loss of contents that might
be caused under normal conditions of transport by vibration or by changes in temperature, humidity or
pressure.
(2) The packaging shall consist of at least three components:
(a) a primary receptacle,
(b) a secondary packaging, and
(c) an outer packaging
of which either the secondary or the outer
packaging shall be rigid
The outer packaging must be rigid.
(3) Primary receptacles shall be packed in secondary packagings in such a way that, under normal conditions of
transport, they cannot break, be punctured or leak their contents into the secondary packaging. Secondary
packagings shall be secured in outer packagings with suitable cushioning material. Any leakage of the
contents shall not compromise the integrity of the cushioning material or of the outer packaging.
(4) For transport, the mark illustrated below shall be displayed on the external surface of the outer packaging on a
background of a contrasting colour and shall be clearly visible and legible. The mark shall be in the form of
a square set at an angle of 45° (diamond-shaped) with each side having a length of at least 50 mm; the
width of the line shall be at least 2 mm and the letters and numbers shall be at least 6 mm high. The proper
shipping name “BIOLOGICAL SUBSTANCE, CATEGORY B” in letters at least 6 mm high shall be
marked on the outer packaging adjacent to the diamond-shaped mark.
(5) At least one surface of the outer packaging must have a minimum dimension of 100 mm × 100 mm.
(6) The completed package shall be capable of successfully passing the drop test in 6.3.5.3 as specified in
6.3.5.2 of these Regulations at a height of 1.2 m. Following the appropriate drop sequence, there shall be no
leakage from the primary receptacle(s) which shall remain protected by absorbent material, when required,
in the secondary packaging.
33. 30
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
(7) For liquid substances
(a) The primary receptacle(s) shall be leakproof; and must not contain more than 1 litre;
(b) The secondary packaging shall be leakproof;
(c) If multiple fragile primary receptacles are placed in a single secondary packaging, they shall be
either individually wrapped or separated to prevent contact between them;
(d) Absorbent material shall be placed between the primary receptacle(s) and the secondary packaging.
The absorbent material shall be in quantity sufficient to absorb the entire contents of the primary
receptacle(s) so that any release of the liquid substance will not compromise the integrity of the
cushioning material or of the outer packaging;
(e) The primary receptacle or the secondary
packaging shall be capable of withstanding,
without leakage, an internal pressure of 95
kPa (0.95 bar).
in the range of -40 °C to +55 °C (-40 °F to +130 °F).
(f) The outer package must not contain more than 4
litres. This quantity excludes ice, dry ice or
liquid nitrogen when used to keep specimens
cold.
(8) For solid substances
(a) The primary receptacle(s) shall be siftproof; and must not exceed the outer packaging mass limit;
(b) The secondary packaging shall be siftproof;
(c) If multiple fragile primary receptacles are placed in a single secondary packaging, they shall be
either individually wrapped or separated to prevent contact between them.
(d) Except for packages containing body parts,
organs or whole bodies, the outer package must
not contain more than 4 kg. This quantity
excludes ice, dry ice or liquid nitrogen when used
to keep specimens cold;
(e) If there is any doubt as to whether or not residual liquid may be present in the primary receptacle
during transport then a packaging suitable for liquids, including absorbent materials, shall be used.
(9) Refrigerated or frozen specimens: Ice, dry ice and liquid nitrogen
(a) When dry ice or liquid nitrogen is used as a coolant, the requirements of 5.5.3 shall apply. When
used, ice shall be placed outside the secondary packagings or in the outer packaging or an overpack.
Interior supports shall be provided to secure the secondary packagings in the original position. If ice is
used, the outside packaging or overpack shall be leakproof.
(b) The primary receptacle and the secondary packaging shall maintain their integrity at the temperature of
the refrigerant used as well as the temperatures and the pressures which could result if refrigeration
were lost.
(10) When packages are placed in an overpack, the package markings required by this packing instruction shall
either be clearly visible or be reproduced on the outside of the overpack.
(11) Infectious substances assigned to UN 3373 which are packed and marked in accordance with this packing
instruction are not subject to any other requirement in these Regulations.
Infectious substances assigned to UN 3373 that are
packed and marked in accordance with this packing
instruction are not subject to any other requirement in
these Instructions except for the following:
(a) the name and address of the shipper and the
receiver (consignee) must be provided on each
package;
Continued on next page
34. 31
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
(b) the name and telephone number of a person
responsible must be provided on a written
document (such as an air waybill) or on the
package;
(c) classification must be in accordance with
provision 2;6.3.2 of the ICAO Technical
Instructions;
(d) the incident reporting requirements in provision
7;4.4 of the ICAO Technical Instructions must
be met (these refer to operators);
(e) the inspection for damage or leakage
requirements in provisions 7;3.1.3 and
7;3.1.4 of the ICAO Technical Instructions
(these refer to operators);
(f) passengers and crew members are
prohibited from transporting infectious
substances either as, or in, carry-on baggage
or checked baggage or on their person.
(12) Clear instructions on filling and closing such packages shall be provided by packaging manufacturers and
subsequent distributors to the consignor or to the person who prepares the package (e.g. patient) to enable
the package to be correctly prepared for transport.
(13) Other dangerous goods shall not be packed in the same packaging as Division 6.2 infectious substances
unless they are necessary for maintaining the viability, stabilizing or preventing degradation or neutralizing
the hazards of the infectious substances. A quantity of 30 ml or less of dangerous goods included in Classes
3 (flammable liquids), 8 (corrosives) or 9 (miscellaneous dangerous substances and articles, including
environmentally hazardous substances) may be packed in each primary receptacle containing infectious
substances. When these small quantities of dangerous goods are packed with infectious substances in
accordance with this packing instruction no other requirements in these Instructions need be met.
Additionalrequirement:
Alternative packagings for the transport of animal material may be authorized by the competent authority in
accordance with the provisions of 4.1.3.7.
35. 32
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 5
List of dangerous goods related to the transport of infectious
substances
Passenger and cargo aircraft Cargo aircraft only
Limited quantity
Proper Shipping Name
UN
No.
Class
or Div
Sub
Risk
Hazard
Labels
State
Var
SP
UN
Pkg
Grp
Pkg
Inst
Max net
Qty/ Pkg
Pkg
Inst
Max net
Qty/ Pkg
Pkg
Inst
Max net
Qty/ Pkg
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Aviation regulated liquid, n.o.s. 3334 9 Misc. A27 Y964 30 kg G 964 450 L 964 450 L
Biological substance, Category B 3373 6.2 None GB 5 see 650 see 650
(Bio) medical waste 3291 6.2 Inf. A117 II 622 No limit 622 No limit
Carbon dioxide, solid
Dry ice
1845 9 Misc.
A48
A151
954 200 kg 954 200 kg
Clinical waste, unspecified, n.o.s. 3291 6.2 Inf. A117 II 622 No limit 622 No limit
Ethanol
Ethanol solution
Ethyl alcohol
Ethyl alcohol solution
1170 3
Flamm
Liq
A3
A58
II
Y341 1 litre
353 5 litres 364 60 litres
A180 III
Y344 10 litres
355 60 litres
366
220 litres
Formaldehyde solution, with not
less than 25% formaldehyde
2209 8 Corrsv US 4 III Y841 1 litre 852 5 litres 856 60 litres
Formaldehyde solution,
flammable
1198 3 8
Flam
m Liq
&
C
A180 III Y342 1 litre 354 5 litres 365 60 litres
Genetically modified micro-
organisms
Genetically modified organisms
3245 9 Misc. A47 959 No limit 959 No limit
Infectious substance, affecting
animals only
2900 6.2 Inf.
AU 3;
CA 8;
VU 2
A81
A140
620
50 ml or
50 g
620
4 litres ro
4 kg
Infectious substance, affecting
humans
2814 6.2 Inf.
AU 3;
CA 8;
VU 2
A81
A140
620
50 ml or
50 g
620
4 litres or
4 kg
Medical waste, n.o.s. 3291 6.2 Inf. A117 II 622 No limit 622 No limit
Methanol 1230 3 6.1
Flamm
liquid
A104
A113
II
Y341 1 litre
352 1 litre 364 60 litres
Nitrogen, refrigerated liquid 1977 2.2
Non-
flamm
gas
A152 202 50 kg 202 500 kg
Regulated medical waste, n.o.s. 3291 6.2 Inf. A117 II 622 No limit 622 No limit
36. 33
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 6
Special Provisions applicable to certain substances
The following Special Provisions are listed according to ICAO (UN):
A3 (223) If the chemical or physical properties of a substance covered by this description are
such that, when tested, it does not meet the established defining criteria for the
class or division listed in column 3, or any other class or division, it is not subject to
Dangerous Goods Regulations.
A27 (276) This includes any substance which is not covered by any of the other classes but
which has narcotic, noxious or other properties such that, in the event of spillage or
leakage on an aircraft, extreme annoyance or discomfort could be caused to crew
members so as to prevent the correct performance of assigned duties.
A47 (219) Genetically modified micro-organisms (GMMOs) and genetically modified organisms
(GMOs) packed and marked in accordance with Packing Instruction 959 are not subject
to any other requirements in the Dangerous Goods Regulations.
If GMMOs and GMOs meet the definition in 2.6 of a toxic substance or an infections
substance and meet the criteria for inclusion in Division 6.1 or 6.2, the requirements in
the Dangerous Goods Regulations for transporting toxic substances or infectious
substances apply.
A48 Packaging tests are not considered necessary.
A58 (144) An aqueous solution containing not more than 24% alcohol by volume is not subject to
Dangerous Goods Regulations.
A81 The quantity limits shown in columns 12 and 14 do not apply to body parts, organs or
whole bodies.
A104 A toxic subsidiary risk label, although not required by Dangerous Goods Regulations,
may be applied.
A113 (279) The substance is assigned to this classification or packing group based on human
experience rather than the strict application of classification criteria set out in the
Dangerous Goods Regulations.
A117: Wastes transported under UN 3291 are wastes derived from the medical treatment of
humans or animals or from bio-research, where there is a relatively low probability that
infectious substances are present. Waste infectious substances which can be specified
must be assigned to UN 2814 or UN 2900. Decontaminated wastes which previously
contained infectious substances may be considered as not subject to Dangerous Goods
Regulations unless the criteria of another class or division are met.
A140 (318) For the purposes of documentation, the proper shipping name must be supplemented
with the technical name. Technical names need not be shown on the package. When the
infectious substances to be transported are unknown, but suspected of meeting the
criteria for inclusion in category A and assignment to UN 2814 or UN 2900, the words
“suspected category A infectious substance” must be shown, in parenthesis, following
the proper shipping name on the transport document, but not on the outer packagings.
37. 34
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
A151 When dry ice is used as a refrigerant for other than dangerous goods loaded in a unit load
device or other type of pallet, the quantity limits per package shown in columns 12 and
14 of the table in Annex 5 for dry ice do not apply. In such case, the unit load device or
other type of pallet must be identified to the operator and must allow the venting of the
carbon dioxide gas to prevent a dangerous build-up of pressure.
A152 Insulated packagings conforming to the requirements of Packing Instruction 202
containing refrigerated liquid nitrogen fully absorbed in a porous material are not subject
to Dangerous Goods Regulations provided the design of the insulated packaging would
not allow the build-up of pressure within the container and would not permit the release
of any refrigerated liquid nitrogen irrespective of the orientation of the insulated
packaging and any outer packaging or overpack used is closed in a way that will not
allow the build-up of pressure within that packaging or overpack. When used to contain
substances not subject to Dangerous Goods Regulations, the words “Not Restricted” and
the special provision number A152 must be provided on the air waybill when an air
waybill is issued.
A180 Non-infectious specimens, such as specimens of mammals, birds, amphibians, reptiles,
fish, insects and other invertebrates containing small quantities of UN 1170 (Ethanol),
UN 1198 (Formaldehyde solution, flammable), UN 1987 (Alcohols, n.o.s.) or UN 1219
(Isopropanol) are not subject to Dangerous Goods Regulations provided the following
packing and marking requirements are met:
a) specimens are:
1. wrapped in paper towel and/or cheesecloth moistened with alcohol or an
alcohol solution and then placed in a plastic bag that is heat-sealed. Any free
liquid in the bag must not exceed 30 ml; or
2. placed in vials or other rigid containers with no more than 30 ml of alcohol or
an alcohol solution;
b) the prepared specimens are then placed in a plastic bag that is then heat-sealed;
c) the bagged specimens are then placed inside another plastic bag with absorbent
material then heat-sealed;
d) the finished bag is then placed in a strong outer packaging with suitable cushioning
material;
e) the total quantity of flammable liquid per outer packaging must not exceed 1 litre;
and
f) the completed package is marked “scientific research specimens, not restricted.
Special Provision A180 applies”.
The words “not restricted” and the special provision number A180 must be provided
on the air waybill when an air waybill is issued.
38. 35
WHO/HSE/GCR/2015.2 Guidance on regulations for the transport of infectious substances 2015–2016
Annex 7
Flowchart for the classification of infectious substances
and patient specimens
Substance for classification
Is it known not to contain infectious substances?
Have any pathogens present been neutralized or inactivated, so that they no longer pose a health
risk?
May it contain microorganisms that are non-pathogenic to humans or animals?
Is it in a form in which any pathogens present have been neutralized or inactivated such that they
no longer pose a health risk?
Is it an environmental sample (including food and water sample) that is not considered to pose a
significant risk of infection?
Is it a dried blood spot?
Is it a faecal occult blood screening sample?
Is it decontaminated medial or clinical waste?
Is it for transfusion or transplantation?
Yes No or
Unknown
Does it meet the definition of
a Category A substance?
No
Has an informed professional judgement based on the
known medical history, symptoms and individual
circumstances of the source, human or animal, and
endemic conditions determined that there is only
minimal likelihood that pathogens are present?
Yes or
Unknown
Yes No or
Unknown
Not subject to the
transport requirements
for dangerous goods
unless meeting the
criteria for another
division or class
Subject to 'Exempt
human specimen' or
'Exempt animal
specimen' provisions
UN 3373 Biological
substance, Category B
UN 2814 Infectious
substance, affecting
humans, or
UN 2900 Infectious
substance, affecting
animals only